

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Thyroid Disorders and Breast Cancer Risk in Asian Population: A Nationwide Population-Based Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020194
Article Type:	Research
Date Submitted by the Author:	19-Oct-2017
Complete List of Authors:	Weng, Chien-Hsiang; Brown University Warren Alpert Medical School, Family Medicine Chen, Yi-Huei ; Taichung Veterans General Hospital, Medical Research Luo, Xun; Johns Hopkins School of Medicine, Surgery Lin, Ching-Heng ; Taichung Veterans General Hospital, Medical Research Lin, Tseng-Hsi ; Taichung Veterans General Hospital, Pathology and Laboratory Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Oncology, Public health
Keywords:	Thyroid disease < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Breast tumours < ONCOLOGY, PREVENTIVE MEDICINE

SCHOLARONE™
Manuscripts

1

2

3 1 **Thyroid Disorders and Breast Cancer Risk in Asian Population:**

4

5

6 2 **A Nationwide Population-Based Study**

7

8

9 3

10

11

12 4 Chien-Hsiang Weng^{1,2,3,†}, Yi-Huei Chen⁴, Dr. Xun Luo³,

13

14 5 Ching-Heng Lin⁴, Tseng-Hsi Lin^{5,6,†}

15

16 6

17

18

19 7 ¹ Department of Family Medicine, Brown University Warren Alpert Medical School.

20

21 8 Pawtucket, RI 02860, USA

22

23

24 9 ² NH Dartmouth Family Medicine Residency, Concord Hospital. Concord, NH 03301,

25

26 10 USA

27

28

29 11 ³ Department of Surgery, Johns Hopkins University School of Medicine. Baltimore, MD

30

31 12 21205, USA

32

33

34 13 ⁴ Department of Medical Research, Taichung Veterans General Hospital. Taichung

35

36 14 40705, TAIWAN

37

38

39 15 ⁵ Division of Hematology/Oncology, Department of Internal Medicine, Taichung Veterans

40

41 16 General Hospital. Taichung 40705, TAIWAN

42

43

44

45 17 ⁶ Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine,

46

47 18 Taichung Veterans General Hospital. Taichung 40705, TAIWAN

48

49

50 19 [†] Chien-Hsiang Weng and Tseng-Hsi Lin contributed as co-senior authors to this article.

51

21

Key words: hyperthyroidism; hypothyroidism; breast cancer; cancer risk

23

Corresponding to:

Tseng-Hsi Lin, MD, PhD

Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine

Taichung Veterans General Hospital, Taichung, Taiwan

Address: 1650 Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan

Telephone: +886-4-23592525 ext. 3380

Fax: +886-4-23559018

E-mail: jth.lin@gmail.com

32

33

34

Word count: 2350

36

37

38

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To evaluate whether hyper- or hypothyroidism increases the risk of subsequent breast cancer in an Asian population.

Design: Nationwide population-based case-control study.

Setting: All health care facilities in Taiwan.

Participants: A total of 103,466 women (mean age 53.3 years) were enrolled.

Methods: 51,733 adult women with newly diagnosed with primary breast cancer without a previous cancer history between 2006 and 2011 were identified and included in our study. 51,733 women with no cancer diagnosis prior to the index date were age-matched as controls. Diagnosis of hyper- or hypothyroidism prior to the diagnosis of breast cancer or the same index date was identified, age, histories of thyroid disease treatment, estrogen use and radioactive-iodine treatment were adjusted.

Main outcome measures: To identify risk differences in developing breast cancer among patients with a medical history of hyper- or hypothyroidism.

Results: There was a significantly increased risk of breast cancer in women with hyperthyroidism under age of 55 years (age <45: OR 1.16, p=0.049; age 45-55: OR 1.15, p=0.019). Patients with hypothyroidism also showed an increased risk of breast cancer (OR 1.19, p=0.029) without statistical significance after stratification by age group (age <45, 45-55, >55 years). Treatment for thyroid disorders did not alter the association in subgroup analyses (p=0.857; 0.262 respectively).

Conclusions: Asian women under 55 years of age with history of hyperthyroidism have a significantly increased risk of breast cancer regardless of treatment. Women with history of hypothyroidism may also have an increased risk.

Strengths and limitations of this study

- This is the first study in an Asian population assessing the association between hyperthyroidism, hypothyroidism, breast cancer, and age.
- Asian women under 55 years of age with history of hyperthyroidism have a significantly increased risk of breast cancer regardless of treatment. Women with history of hypothyroidism may also have an increased risk.
- Treatment for hyper- or hypothyroidism did not alter this association.
- The most important limitation of this study is the characteristic of the database. Since it is a national health insurance claims database, detailed TSH, T4, T3 level, types and stages of breast cancer are not available for further stratification and analysis.

1

2

380INTRODUCTION

4

5

681One in eight women will develop breast cancer in their lifetime, a disease prevalence

7

882similar to the risk of thyroid disorders in this population.¹⁻³ Since high thyroid hormone

9

1083levels are found to have estrogen-like effects in several *in vitro* studies, thyroid hormone

11

1284levels and their relation to the development of breast and other cancers have been

13

1485studied in the past with conflicting results and primarily in Caucasian populations.⁴⁻¹⁴

15

16

17

1886

19

20

2187This is the first study conducted to assess the association between hyperthyroidism,

22

2388hypothyroidism and breast cancer in an Asian population. We designed a nationwide

24

2589population-based case-control study utilizing the Taiwanese National Health Insurance

26

2790Research Database (NHIRD), one of the largest administrative health care databases in

28

2991the world; our aim was to discover the relationship between hyper- or hypothyroidism

30

3192and breast cancer from the epidemiological aspect.

32

33

34

35

3693

37

38

3994

40

41

4295

43

44

4596

46

47

4897

49

50

5198

52

53

5499

55

56

57

58

59

60

METHODS

We designed a case-control study utilizing the Taiwanese National Health Insurance Research Database (NHIRD). Female patients with a new diagnosis of primary breast cancer and no previous cancer history were identified from the NHIRD (diagnosed between 2006 and 2011). Age-matched female individuals without a breast cancer diagnosis were randomly selected as controls. We then identified the status of thyroid disorders prior to the diagnosis of breast cancer in the case group or the same index date in the control group. We excluded those with a history of a thyroid malignancy. (Figure 1)

Taiwanese National Health Insurance Research Database (NHIRD)

The National Health Insurance program was established in Taiwan in March 1995 and covers about 99% of the Taiwanese population. The National Health Insurance Research Database (NHIRD), established by the National Health Research Institute (NHRI), is a claims database maintained by the Department of Health and the NHRI. There are several subset databases in the NHIRD including the Registry for Catastrophic Illness Patient Database (RCIPD). Breast cancer is defined as a catastrophic illness by the government. Thus, when patients are diagnosed with breast cancer, they will apply and register for the certificate of catastrophic illness.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

120 The Longitudinal Health Insurance Database (LHID) is a database of one million
121 randomly selected insurers from the NHIRD. We used the 2010 version of the LHID
122 which included 1,000,000 individuals randomly selected from the total of 23,251,700
123 insured.

124
Breast cancer

126 In order to identify patients with newly diagnosed primary breast cancer, we searched
127 the NHIRD by using the International Classification of Diseases, 9th Revision, Clinical
128 Modification (ICD9-CM) code 174 and 175, cross-linking these to the RCIPD. The
129 identified patients all had newly diagnosed breast cancer between 2006 and 2011 and
130 possessed a certificate of catastrophic illness. There were 53,488 total patients
131 identified.

132 We then excluded male gender, age unknown, sex unknown, or age < 18 or >120 years
133 old at the time of diagnosis. We excluded patients with diagnoses of other malignant
134 diseases before the diagnosis of breast cancer. A total of 51,733 patients were
135 identified from the NHIRD by the above criteria as cases.

136
Case-control match

138 We applied a one-to-one match for the control group, randomly matched for age, sex,
139 and the same index date (the month and year of breast cancer diagnosis in the case
140 group) from the LHID. We excluded male gender, age unknown, sex unknown, age < 18

or >120 years old at time of index date, or deceased before index date. We excluded patients with the diagnosis of breast cancer. Also excluded patients were those with diagnoses of other malignant diseases before the index date. A total of 51,733 women were selected as controls.

Hyperthyroidism and hypothyroidism

To identify patients with the diagnosis of hyperthyroidism, we used the ICD9-CM code 242 with additional criteria including the same diagnosis in at least three outpatient visits or one inpatient admission. We stipulated that the first diagnosis of hyperthyroidism had to occur before the date of first breast cancer diagnosis in the case group or the index date in the control group. We used the ICD9-CM codes 243 and 244 with the same additional criteria to identify patients with hypothyroidism. We also excluded patients with ICD9-CM codes 244.0, 244.1, 244.2, 244.3 in the hypothyroidism group since those are acquired hypothyroidism. We identified a specific group of patients with both hyperthyroidism (ICD9-CM 242) and hypothyroidism diagnoses (ICD9-CM 244.0, 244.1, 244.2, 244.3), which represents acquired hypothyroidism from hyperthyroidism treatments. We excluded those with a diagnosis of thyroid malignancy in our study.

Other adjustments

We adjusted for estrogen use or hormone replacement therapy, a history of radioactive iodine treatment, medication or surgical treatment for thyroid disease, and age. We identified the use of hyperthyroidism, hypothyroidism medications, estrogen-containing

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

163 products including oral forms, injection forms, or external-use forms available on the
164 market in Taiwan, and labeled them as ever-used versus never-used. We did not
165 calculate the length of use in each female since it is very difficult to know their
166 compliance and effects between different products. We also identified females who
167 have ever received radioactive iodine treatment and adjusted it in our analysis.

168
169 **Statistical analysis**

170 To examine the differences in clinical characteristics between breast cancer and control
171 groups, we used the Student's t-test to analyze continuous variables and the chi-square
172 test to analyze categorical variables. Conditional logistic regression analysis was
173 applied to examine the effect of thyroid disorders, including hyperthyroidism,
174 hypothyroidism, and acquired hypothyroidism, on the risk of developing breast cancer,
175 and controlled for potential confounders. Logistic regression analysis was applied to
176 examine the associations between treatments for hyperthyroidism or hypothyroidism
177 and the risk of developing breast cancer in subgroup analysis. All statistical tests were
178 two-sided, conducted at a significance level of 0.05, and reported using *p*-values and/or
179 95% confidence intervals (95% CI). All analyses were performed using Statistical
180 Analytic System (SAS) software version 9.4 (SAS Institute, Cary, NC, USA).

RESULTS

A total of 103,466 patients were enrolled in our study, 51,733 in each group. As for patient characteristics, the mean ages were 53.4 years and 53.3 years in the breast cancer and control groups, respectively ($p=0.137$). In the breast cancer group, 36.9% of the patients had ever used estrogen-containing medications; in the control group, 41.6% of patients had ever used estrogen-containing medications ($p<0.001$). Prior to the time of breast cancer diagnosis or the index date, 46 and 42 women received radioactive iodine treatment in the breast cancer and control groups, respectively ($p=0.67$). Significant differences in the proportions of thyroid disorders in the breast cancer group and control group were found ($p=0.022$). There were 335 patients (0.7%) with hypothyroidism in the breast cancer group and 291 patients (0.6%) in the control group. A total of 1580 patients (3.1%) had the diagnosis of hyperthyroidism in the breast cancer group and 1453 patients (2.8%) in the control group. (Table 1)

Table 1. Clinical characteristics of study subjects with and without breast cancer

Variable	Total (N=103,466)		Without breast cancer (N=51,733)		With breast cancer (N=51,733)		<i>p</i> value
	n	(%)	n	(%)	n	(%)	
Age, years (mean \pm SD)	53.3 \pm 12.1		53.3 \pm 12.2		53.4 \pm 12.0		0.137 [†]
Gender							—

1							
2							
3	Female	103466	(100.0)	51733	(100.0)	51733	(100.0)
4							
5	Male	0	(0.0)	0	(0.0)	0	(0.0)
6							
7	Thyroid disorders						0.022
8	No	93675	(91.0)	46866	(91.0)	46809	(90.9)
9	With Hypothyroidism	626	(0.6)	291	(0.6)	335	(0.7)
10	With Hyperthyroidism	3033	(2.9)	1453	(2.8)	1580	(3.1)
11	With Acquired Hypothyroidism	161	(0.2)	87	(0.2)	74	(0.1)
12	Others	5462	(5.3)	2782	(5.4)	2680	(5.2)
13							
14	History of estrogen use						<0.001
15	No	62834	(60.7)	30197	(58.4)	32637	(63.1)
16	Yes	40632	(39.3)	21536	(41.6)	19096	(36.9)
17							
18	History of radioactive iodine treatment						0.670
19	No	103378	(99.9)	51691	(99.9)	51687	(99.9)
20	Yes	88	(0.1)	42	(0.1)	46	(0.1)
21							
22	Medication treatment for thyroid disorder						0.510
23	No	100569	(97.2)	50302	(97.2)	50267	(97.2)
24	Yes	2897	(2.8)	1431	(2.8)	1466	(2.8)
25							
26	Thyroidectomy						0.330
27	No	102307	(98.9)	51137	(98.8)	51170	(98.9)
28	Yes	1159	(1.1)	596	(1.2)	563	(1.1)

+ T test; chi-squared test for all other *p-values*.

Acquired Hypothyroidism: with diagnoses of hyperthyroidism + hypothyroidism.

200

201

202 Both hyperthyroidism and hypothyroidism were associated with an increased risk of

203 developing breast cancer after adjusting for age, estrogen-containing medication use,

204 and a history of radioactive iodine treatment. Hyperthyroidism in all age groups showed

205 an overall increased risk by 12% in breast cancer development (OR 1.12, 95% CI 1.04-

1.20, $p=0.003$), while hypothyroidism in all age groups had a 19% increased risk (OR 1.19, 95% CI 1.02-1.40, $p=0.029$). No significant change in risk was found among those who had acquired hypothyroidism after treatment for hyperthyroidism (OR 0.88, 95% CI 0.64-1.22, $p=0.453$).

When we stratified by age group (age<45, age 45-55, age>55 years), patients with hyperthyroidism aged 55 or under showed a significantly increased breast cancer risk; this association disappeared in those aged 55 years and older. Among patients aged <45 years, there was a 16% increased risk in breast cancer (OR 1.16, 95% CI 1.00-1.34, $p=0.049$). In those aged 45-55 years there was a 15% increased risk (OR 1.15, 95% CI 1.02-1.29, $p=0.019$). The increased odds for breast cancer in patients with hypothyroidism did not reach statistical significance among those 3 age groups. (Table 2)

Table 2. Adjusted odds ratio of breast cancer associated with thyroid disorders

Variable	Adjusted OR	95% CI	<i>p</i> value
Overall			
Without Thyroid disorders	1.00	—	—
With Hypothyroidism	1.19	(1.02-1.40)	0.029
Without Thyroid disorders	1.00	—	—
With Hyperthyroidism	1.12	(1.04-1.20)	0.003
Without Thyroid disorders	1.00	—	—
With Acquired Hypothyroidism	0.88	(0.64-1.22)	0.453
Without Thyroid disorders	1.00	—	—
Others	0.99	(0.94-1.05)	0.806

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Age < 45			
Without Thyroid disorders	1.00	—	—
With Hypothyroidism	1.07	(0.71-1.60)	0.757
Without Thyroid disorders	1.00	—	—
With Hyperthyroidism	1.16	(1.00-1.34)	0.049
Without Thyroid disorders	1.00	—	—
With Acquired Hypothyroidism	0.62	(0.29-1.32)	0.214
Without Thyroid disorders	1.00	—	—
Others	1.03	(0.91-1.16)	0.692
Age 45-55			
Without Thyroid disorders	1.00	—	—
With Hypothyroidism	1.18	(0.90-1.54)	0.226
Without Thyroid disorders	1.00	—	—
With Hyperthyroidism	1.15	(1.02-1.29)	0.019
Without Thyroid disorders	1.00	—	—
With Acquired Hypothyroidism	0.84	(0.50-1.43)	0.532
Without Thyroid disorders	1.00	—	—
Others	1.05	(0.96-1.15)	0.276
Age ≥ 56			
Without Thyroid disorders	1.00	—	—
With Hypothyroidism	1.23	(0.98-1.54)	0.070
Without Thyroid disorders	1.00	—	—
With Hyperthyroidism	1.05	(0.93-1.19)	0.454
Without Thyroid disorders	1.00	—	—
With Acquired Hypothyroidism	1.07	(0.65-1.76)	0.792
Without Thyroid disorders	1.00	—	—
Others	0.92	(0.84-1.00)	0.052

Adjusted OR was adjusted for age, estrogen use, and history of Iodine treatment by logistic regression analysis.

In the subgroup analysis, we examined whether medication and/or surgical treatment for hyper- or hypothyroidism would change the risk of having breast cancer. The

analysis showed no statistically significant differences between treatments for hyper- or hypothyroidism and the risk of developing breast cancer (OR 1.01, 95% CI 0.88-1.17, $p=0.857$; OR 0.80, 95% CI 0.54-1.18, $p=0.262$; respectively). (Table 3)

Table 3. Subgroup analysis for treatment - adjusted odds ratio of breast cancer associated with thyroid disorders (TD)

Variable	Adjusted OR	95% CI	<i>p</i> value
Subjects with Hypothyroidism			
Without TD medications	1.00	—	—
With TD medications ¹	0.80	(0.54-1.18)	0.262
Subjects with Hyperthyroidism			
Without TD medications and surgery	1.00	—	—
With TD medications ² or surgery ³	1.01	(0.88-1.17)	0.857
Subjects with Hyperthyroidism			
Without TD medications and surgery	1.00	—	—
With surgery ⁴	0.97	(0.74-1.27)	0.825
With TD medications	1.02	(0.88-1.19)	0.789

Adjusted OR was adjusted for age, estrogen use, and history of Iodine treatment by logistic regression analysis.

¹ Hypothyroidism medication: levothyroxine.

² Hyperthyroidism medications: methimazole, propylthiouracil (did not include radioactive iodine treatment since it was adjusted separately).

³ Surgery: thyroidectomy (partial or total).

⁴ If the patient received both medication and surgical treatment, the patient would be classified as surgical patient in this subgroup.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

230

231

232 **DISCUSSION**

233 This is the first study in an Asian population assessing the association between

234 hyperthyroidism, hypothyroidism and breast cancer. Among a total of 103,466 women in

235 our study, we found increased risks of developing breast cancer in patients with medical

236 history of either hyperthyroidism or hypothyroidism despite treatment. The association is

237 significant in patients under age 55 years old with hyperthyroidism.

238

239 We also performed a separate analysis for autoimmune thyroid disease- Hashimoto's

240 thyroiditis and Graves' disease, to examine the association with breast cancer but found

241 no statistical significance (OR 0.94, 95% CI 0.68-1.29, p=0.685 for Hashimoto; OR 1.20,

242 95% CI 0.96-1.50, p=0.109 for Graves').

243

244 Since Beaston first described using thyroid extract to treat metastatic breast cancer in

245 the Lancet in 1896, many studies have investigated the relationship between thyroid

246 hormone and cancers.^{15 16} Specific alterations of thyroid hormone receptors (TR) have

247 been found in different types of carcinomas, including breast cancer, and many studies

248 observed associations between the expression of TRs and the regulation of

249 oncogenes.¹⁶⁻¹⁸ Several physiological similarities have been discovered between the

250 thyroid gland and mammary gland. For one, both thyroid follicular cells and breast

lactating cells store iodine through natrium-iodine symporter (NIS)-mediated iodine uptake.¹⁹⁻²² The oxidization of iodine in the alveolar mammary cells utilizes lactohydroperoxidase, which is mechanistically similar to hydroperoxidase in thyroid glands.²³

Several *in vitro* studies have shown that high levels of thyroid hormones may possess estrogen-like effects and may promote breast cancer proliferation and angiogenesis.^{5 13} It has also been shown that the activation of TR in mammary glands may induce the differentiation and lobular growth of breast tissues, an effect similar to that seen with estrogen.^{16 17} Active triiodothyronine (T3) has been found to promote breast cancer cell proliferation and to increase the effect of 17beta-estradiol (E2)-mediated cell proliferation in some breast cancer cell lines.¹³ In population-based studies, T3 levels have also been found to have a positive correlation with breast cancer tumor size and the risk of lymph node metastasis.²⁵

Hypothyroidism may lead to hypersensitization of mammary glandular epithelium to estrogen and prolactin, possibly related to low circulating thyroid hormone.²⁶ Some studies have proposed that there could be different set points for thyroid function in women with higher risks of breast cancer; specifically, they may have lower free T4 and low-normal TSH levels without clinical symptoms.^{6 27} The existence of a genetic predisposition for hypothyroidism and breast cancer has been hypothesized as well.¹⁰

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In our study, the significantly increased risk of breast cancer among patients with the diagnosis of hyperthyroidism under 55 years of age is possibly related to higher levels of thyroid hormone in addition to the physiological level of estrogen. The increased risk drops from 15-16% to 5% with no statistical significance in hyperthyroidism patients >55 years of age. This is likely related to the menopausal status of these patients, an indicator of low estrogen levels. In the further subgroup analysis, we found that hyperthyroidism treatment with medications and/or surgery and thyroid replacement treatment for hypothyroidism did not alter the risk of having breast cancer in the future. While there is a 19% increased risk of breast cancer in hypothyroidism patients, the statistical significance disappears when we stratify these patients into the 3 age groups. Since there were only 335 patients with a diagnosis of hypothyroidism who developed breast cancer, dividing this group into 3 age cohorts led to a decrease in power. Based on our overall results, however, we can hypothesize that there is no protective effect of hypothyroidism in the development of breast cancer. Interestingly, the use of estrogen-containing products (which we controlled for) was not a contributing factor to an increased risk of breast cancer in this study.

In 2016, it is estimated that 40,450 women may die of breast cancer in the U.S.¹ Current breast cancer screening guidelines published by the U.S. Preventive Services Task Force (USPSTF) recommend biennial screening mammography for women at average risk aged 50 to 74 years.²⁸ The American Cancer Society (ACS) recommends annual screening mammography for women at average risk aged 45 to 55 years then biennial screening after 55 years of age.²⁹ Our nationwide population-based study showed a

significantly increased breast cancer risk in women with hyperthyroidism under the age of 55 years and an increased risk or at least no protective effect of hypothyroidism. More large studies are needed to examine this association in different age groups.

Limitations

The findings from our study were derived from a large population-based dataset; this minimized selection bias. The case-control study design using an administrative claims database reduced the recall bias; however, the findings might be less accurate due to the lack of supporting laboratory data; this includes thyroid antibody, TSH and thyroid hormones levels as well as breast cancer stages and receptor status. In order to minimize bias, we only studied those with a diagnosis of hyper- or hypothyroidism who were documented as having these diagnoses in at least three outpatient visits or one inpatient admission. All breast cancer patients in this study had the diagnosis of breast cancer and possessed the certificate of catastrophic illness. To avoid false claims, the National Health Insurance Bureau (NHIB) randomly samples a fixed percentage of claims from each hospital every year to confirm diagnosis validity, and medical records were independently reviewed by professional experts. Since this study is based on administrative claims, the results may be underestimated or overestimated, as only patients who seek medical attention were evaluated and treated. Since thyroid disorders are often chronic diseases rather than acute onset, we thought that it might not be as useful to adjust the time lapse from the diagnosis of thyroid disorder to breast cancer.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

Our nationwide Asian population-based study suggests that Asian women under the age of 55 years with medical history of hyperthyroidism have a significantly increased risk of developing breast cancer regardless of treatment. Women with a history of hypothyroidism may also have an increased risk. Further studies are needed to assess the association between age, hypothyroidism, and breast cancer risk.

334

335

336

Author contributions:**Concept of study:** C-H Weng and T-H Lin**Study design:** C-H Weng, X Luo, C-H Lin and T-H Lin**Statistical analysis:** Y-H Chen and C-H Lin**Interpretation of results:** C-H Weng, Y-H Chen, X Luo, and C-H Lin**Manuscript writing:** C-H Weng

The other authors provided inputs, expertise, and critical review of the manuscript.

C-H Weng and T-H Lin contributed as co-senior authors to this article.

345

346

Acknowledgements

Special thanks to Professor & Chair Martha A. Zeiger, MD, FACS, FACE, Department of

Surgery, University of Virginia, Professor Christopher B. Umbricht, MD, PhD,

Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore,

1
2
3 351 MD, and Dr. Erin R. Okawa, MD, Boston Childrens Hospital Division of Endocrinology,
4
5 352 Boston, MA, for reviewing the manuscript and their comments.
6
7

8 353 The preliminary results from this study have been presented in part at the 86th Annual
9
10 354 Meeting of the American Thyroid Association in Denver, CO by Chien-Hsiang Weng,
11
12 355 MD, MPH, September 21-25, 2016. Authors thank all the comments and advices from
13
14 356 the conference.
15
16

17
18 357 This study has been approved by the Institutional Review Board of Taichung Veterans
19
20 358 General Hospital, Taichung, Taiwan (IRB # CE13151B-3). The study is based in part on
21
22 359 data from the National Health Insurance Research Database provided by the Bureau of
23
24 360 National Health Insurance, Department of Health and managed by National Health
25
26 361 Research Institutes. The interpretation and conclusions contained herein do not
27
28 362 represent those of National Health Insurance Administration, Department of Health or
29
30 363 National Health Research Institutes.
31
32
33

34
35 364
36
37
38 365 **Declaration of interest:** The authors declare no potential conflicts of interest.
39
40

41 366 **Funding:** This research received no specific grant from any funding agency in the
42
43 367 public, commercial or not-for-profit sectors.
44
45

46
47 368 **Data sharing:** Extra data is available by emailing the Corresponding author
48
49 369 (jth.lin@gmail.com).
50
51

52
53 370
54
55
56
57
58
59
60

References

1. U.S. Breast Cancer Statistics. http://www.breastcancer.org/symptoms/understand_bc/statistics 2016
2. American Thyroid Association. <http://www.thyroid.org/media-main/about-hypothyroidism/> 2016
3. SEER Stat Fact Sheets: Female Breast Cancer, 2016.
4. Khan SR, Chaker L, Ruiter R, et al. Thyroid Function and Cancer Risk: The Rotterdam Study. *J Clin Endocrinol Metab* 2016;101(12):5030-36. doi: 10.1210/jc.2016-2104
5. Sogaard M, Farkas DK, Ehrenstein V, et al. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. *Eur J Endocrinol* 2016;174(4):409-14. doi: 10.1530/EJE-15-0989
6. Kuijpers JL, Nyklictek I, Louwman MW, et al. Hypothyroidism might be related to breast cancer in post-menopausal women. *Thyroid* 2005;15(11):1253-9. doi: 10.1089/thy.2005.15.1253
7. Angelousi AG, Anagnostou VK, Stamatakis MK, et al. Mechanisms in endocrinology: primary HT and risk for breast cancer: a systematic review and meta-analysis. *Eur J Endocrinol* 2012;166(3):373-81. doi: 10.1530/EJE-11-0838

1
2
3 391 8. Tseng FY, Lin WY, Li CI, et al. Subclinical hypothyroidism is associated with increased risk for
4
5
6 392 cancer mortality in adult Taiwanese-a 10 years population-based cohort. *PLoS One*
7
8 393 2015;10(4):e0122955. doi: 10.1371/journal.pone.0122955
9
10
11 394 9. Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. *Cancer*
12
13 395 *Res* 1990;50(8):2283-9.
14
15 396 10. Smyth PP. The thyroid and breast cancer: a significant association? *Ann Med*
16
17 397 1997;29(3):189-91.
18
19
20 398 11. Morabia A, Szklo M, Stewart W, et al. Thyroid hormones and duration of ovulatory activity
21
22 399 in the etiology of breast cancer. *Cancer Epidemiol Biomarkers Prev* 1992;1(5):389-93.
23
24
25 400 12. Tosovic A, Bondeson AG, Bondeson L, et al. Prospectively measured triiodothyronine levels
26
27 401 are positively associated with breast cancer risk in postmenopausal women. *Breast*
28
29 402 *Cancer Res* 2010;12(3):R33. doi: 10.1186/bcr2587
30
31
32 403 13. Hall LC, Salazar EP, Kane SR, et al. Effects of thyroid hormones on human breast cancer cell
33
34 404 proliferation. *J Steroid Biochem Mol Biol* 2008;109(1-2):57-66. doi:
35
36 405 10.1016/j.jsbmb.2007.12.008
37
38
39 406 14. Moeller LC, Fuhrer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical
40
41 407 perspective. *Endocr Relat Cancer* 2013;20(2):R19-29. doi: 10.1530/ERC-12-0219
42
43
44 408 15. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions
45
46 409 for a new method of treatment, with illustrative cases. *The Lancet* 1896;148(3803):162-
47
48 410 65. doi: 10.1016/S0140-6736(01)72384-7
49
50
51 411 16. Conde I, Paniagua R, Zamora J, et al. Influence of thyroid hormone receptors on breast
52
53 412 cancer cell proliferation. *Ann Oncol* 2006;17(1):60-4. doi: 10.1093/annonc/mdj040
54
55
56
57
58
59
60

17. Gonzalez-Sancho JM, Garcia V, Bonilla F, et al. Thyroid hormone receptors/THR genes in human cancer. *Cancer Lett* 2003;192(2):121-32.
18. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. *Oncogene* 2002;21(5):761-8. doi: 10.1038/sj.onc.1205136
19. Smyth PP, Shering SG, Kilbane MT, et al. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. *J Clin Endocrinol Metab* 1998;83(8):2711-6. doi: 10.1210/jcem.83.8.5049
20. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. *Nature* 1996;379(6564):458-60. doi: 10.1038/379458a0
21. Chung JK. Sodium iodide symporter: its role in nuclear medicine. *J Nucl Med* 2002;43(9):1188-200.
22. Turken O, NarIn Y, DemIrbas S, et al. Breast cancer in association with thyroid disorders. *Breast Cancer Res* 2003;5(5):R110-3. doi: 10.1186/bcr609
23. Fierabracci P, Pinchera A, Campani D, et al. Association between breast cancer and autoimmune thyroid disorders: no increase of lymphocytic infiltrates in breast malignant tissues. *J Endocrinol Invest* 2006;29(3):248-51. doi: 10.1007/BF03345548
24. Nogueira CR, Brentani MM. Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. *J Steroid Biochem Mol Biol* 1996;59(3-4):271-9.
25. Tosovic A, Bondeson AG, Bondeson L, et al. T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study. *BMC Cancer* 2014;14:536. doi: 10.1186/1471-2407-14-536

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

26. Vorherr H. Thyroid disease in relation to breast cancer. *Klin Wochenschr* 1978;56(23):1139-45.

27. Andersen S, Pedersen KM, Bruun NH, et al. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. *J Clin Endocrinol Metab* 2002;87(3):1068-72. doi: 10.1210/jcem.87.3.8165

28. Siu AL, Force USPST. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med* 2016;164(4):279-96. doi: 10.7326/M15-2886

29. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. *JAMA* 2015;314(15):1599-614. doi: 10.1001/jama.2015.12783

Figure legend:

Figure 1. Flow Diagram of Participants Selection and Study Design




Figure 1. Flow Diagram of Participants Selection and Study Design

280x115mm (300 x 300 DPI)

BMJ Open

Thyroid Disorders and Breast Cancer Risk in Asian Population: A Nationwide Population-Based Case-Control Study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020194.R1
Article Type:	Research
Date Submitted by the Author:	03-Jan-2018
Complete List of Authors:	Weng, Chien-Hsiang; Brown University Warren Alpert Medical School, Family Medicine Chen, Yi-Huei ; Taichung Veterans General Hospital, Medical Research Lin, Ching-Heng ; Taichung Veterans General Hospital, Medical Research Luo, Xun; Johns Hopkins School of Medicine, Surgery Lin, Tseng-Hsi ; Taichung Veterans General Hospital, Pathology and Laboratory Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Oncology, Public health
Keywords:	Thyroid disease < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Breast tumours < ONCOLOGY, PREVENTIVE MEDICINE

SCHOLARONE™
Manuscripts

Only

1

2

3 1 **Thyroid Disorders and Breast Cancer Risk in Asian Population:**

4

5

6 2 **A Nationwide Population-Based Case-Control Study in Taiwan**

7

8

9 3

10

11

12 4 Chien-Hsiang Weng^{1,2,3,†}, Yi-Huei Chen⁴, Ching-Heng Lin⁴,

13

14 5 Xun Luo³, Tseng-Hsi Lin^{5,6,†}

15

16 6

17

18

19 7 ¹ Department of Family Medicine, Brown University Warren Alpert Medical School.

20

21 8 Pawtucket, RI 02860, USA

22

23

24 9 ² NH Dartmouth Family Medicine Residency, Concord Hospital. Concord, NH 03301,

25

26 10 USA

27

28

29 11 ³ Department of Surgery, Johns Hopkins University School of Medicine. Baltimore, MD

30

31 12 21205, USA

32

33

34 13 ⁴ Department of Medical Research, Taichung Veterans General Hospital. Taichung

35

36 14 40705, TAIWAN

37

38

39 15 ⁵ Division of Hematology/Oncology, Department of Internal Medicine, Taichung Veterans

40

41 16 General Hospital. Taichung 40705, TAIWAN

42

43

44

45 17 ⁶ Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine,

46

47 18 Taichung Veterans General Hospital. Taichung 40705, TAIWAN

48

49

50 19 [†] Chien-Hsiang Weng and Tseng-Hsi Lin contributed as co-senior authors to this article.

51

21

Key words: hyperthyroidism; hypothyroidism; breast cancer; cancer risk

23

Corresponding to:

Tseng-Hsi Lin, MD, PhD

Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine

Taichung Veterans General Hospital, Taichung, Taiwan

Address: 1650 Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan

Telephone: +886-4-23592525 ext. 3380

Fax: +886-4-23559018

E-mail: jth.lin@gmail.com

32

33

34

Word count: 2698

36

37

38

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To evaluate whether hyper- or hypothyroidism increases the risk of subsequent breast cancer in an Asian population.

Design: Nationwide population-based case-control study.

Setting: All health care facilities in Taiwan.

Participants: A total of 103,466 women (mean age 53.3 years) were enrolled.

Methods: 51,733 adult women with newly diagnosed with primary breast cancer without a previous cancer history between 2006 and 2011 were identified and included in our study. 51,733 women with no cancer diagnosis prior to the index date were age-matched as controls. Diagnosis of hyper- or hypothyroidism prior to the diagnosis of breast cancer or the same index date was identified, age, histories of thyroid disease treatment, estrogen use and radioactive-iodine treatment were adjusted.

Main outcome measures: To identify risk differences in developing breast cancer among patients with a medical history of hyper- or hypothyroidism.

Results: There was a significantly increased risk of breast cancer in women with hyperthyroidism under age of 55 years (age <45: OR 1.16, p=0.049; age 45-55: OR 1.15, p=0.019). Patients with hypothyroidism also showed an increased risk of breast cancer (OR 1.19, p=0.029) without statistical significance after stratification by age group (age <45, 45-55, >55 years). Treatment for thyroid disorders did not alter the association in subgroup analyses (p=0.857; 0.262 respectively).

Conclusions: Asian women under 55 years of age with history of hyperthyroidism have a significantly increased risk of breast cancer regardless of treatment. Women with history of hypothyroidism may also have an increased risk.

Strengths and limitations of this study

- This is the first study in an Asian population assessing the association between hyperthyroidism, hypothyroidism, breast cancer, and age.
- The main strength of this study is the large population-based dataset which minimized the selection bias.
- The most important limitation of this study is the characteristic of the database. Since it is a national health insurance claims database, detailed TSH, T4, T3 level, types and stages of breast cancer are not available for further stratification and analysis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

79 **INTRODUCTION**

80 One in eight women will develop breast cancer in their lifetime, a disease prevalence
81 similar to the risk of thyroid disorders in this population.¹⁻³ Since high thyroid hormone
82 levels are found to have estrogen-like effects in several *in vitro* studies, thyroid hormone
83 levels and their relation to the development of breast and other cancers have been
84 studied in the past with conflicting results and primarily in Caucasian populations. Most
85 of the literature published to date have relied on studies of relatively small sample
86 sizes.⁴⁻¹⁴ Sogaard *et al.* published a large study in 2016 utilizing the national registry in
87 Denmark found an increased risk of breast cancer in those who had a medical history of
88 hyperthyroidism without age stratification.⁵

90 Previous observational studies also showed a higher prevalence of hypothyroidism in
91 patients with breast cancer.^{15 16} Older studies proposed that hypothyroidism may induce
92 the breast epithelial cells' sensitivity to prolactin and estrogen.^{17 18} A recent systematic
93 review and meta-analysis included 13 population-based studies with a total of 24,808
94 participants through June 2016 found that either hypothyroidism or hyperthyroidism has
95 no related risk for breast cancer.¹⁹

97 We conducted the first study in an Asian population In order to assess the association
98 between hyperthyroidism, hypothyroidism and breast cancer in different age groups. It
99 is a nationwide population-based case-control study utilizing the Taiwanese National
100 Health Insurance Research Database (NHIRD), one of the largest administrative health

care databases in the world; our aim was to discover the relationship between hyper- or
hypothyroidism and breast cancer from the epidemiological aspect.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

119 **METHODS**

120 We designed a case-control study utilizing the Taiwanese National Health Insurance
121 Research Database (NHIRD). Female patients with a new diagnosis of primary breast
122 cancer and no previous cancer history were identified from the NHIRD (diagnosed
123 between 2006 and 2011). Age-matched female individuals without a breast cancer
124 diagnosis were randomly selected as controls. We then identified the status of thyroid
125 disorders prior to the diagnosis of breast cancer in the case group or the same index
126 date in the control group. We excluded those with a history of a thyroid malignancy.
127 (Figure 1)

129 **Taiwanese National Health Insurance Research Database (NHIRD)**

130 The National Health Insurance program was established in Taiwan in March 1995 and
131 covers about 99% of the Taiwanese population. The National Health Insurance
132 Research Database (NHIRD), established by the National Health Research Institute
133 (NHRI), is a claims database maintained by the Department of Health and the NHRI.
134 There are several subset databases in the NHIRD including the Registry for
135 Catastrophic Illness Patient Database (RCIPD). Breast cancer is defined as a
136 catastrophic illness by the government. Thus, when patients are diagnosed with breast
137 cancer, they will apply and register for the certificate of catastrophic illness.

The Longitudinal Health Insurance Database (LHID) is a database of one million randomly selected insurers from the NHIRD. We used the 2010 version of the LHID which included 1,000,000 individuals randomly selected from the total of 23,251,700 insured.

Breast cancer

In order to identify patients with newly diagnosed primary breast cancer, we searched the NHIRD by using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD9-CM) code 174 and 175, cross-linking these to the RCIPD. The identified patients all had newly diagnosed breast cancer between 2006 and 2011 and possessed a certificate of catastrophic illness. There were 53,488 total patients identified.

We then excluded male gender, age unknown, sex unknown, or age < 18 or >120 years old at the time of diagnosis. We excluded patients with diagnoses of other malignant diseases before the diagnosis of breast cancer. A total of 51,733 patients were identified from the NHIRD by the above criteria as cases.

Case-control match

We applied a one-to-one match for the control group, randomly matched for age, sex, and the same index date (the month and year of breast cancer diagnosis in the case group) from the LHID. We excluded male gender, age unknown, sex unknown, age < 18

or >120 years old at time of index date, or deceased before index date. We excluded patients with the diagnosis of breast cancer. Also excluded patients were those with diagnoses of other malignant diseases before the index date. A total of 51,733 women were selected as controls.

Hyperthyroidism and hypothyroidism

To identify patients with the diagnosis of hyperthyroidism, we used the ICD9-CM code 242 with additional criteria including the same diagnosis in at least three outpatient visits or one inpatient admission. We stipulated that the first diagnosis of hyperthyroidism had to occur before the date of first breast cancer diagnosis in the case group or the index date in the control group. We used the ICD9-CM codes 243 and 244 with the same additional criteria to identify patients with hypothyroidism. We also excluded patients with ICD9-CM codes 244.0, 244.1, 244.2, 244.3 in the hypothyroidism group since those are acquired hypothyroidism. We identified a specific group of patients with both hyperthyroidism (ICD9-CM 242) and hypothyroidism diagnoses (ICD9-CM 244.0, 244.1, 244.2, 244.3), which represents acquired hypothyroidism from hyperthyroidism treatments. We excluded those with a diagnosis of thyroid malignancy in our study.

Other adjustments

We adjusted for estrogen use or hormone replacement therapy, a history of radioactive iodine treatment, medication or surgical treatment for thyroid disease, and age. We identified the use of hyperthyroidism, hypothyroidism medications, estrogen-containing

products including oral forms, injection forms, or external-use forms available on the market in Taiwan, and labeled them as ever-used versus never-used. We did not calculate the length of use in each female since it is very difficult to know their compliance and effects between different products. We also identified females who have ever received radioactive iodine treatment and adjusted it in our analysis.

Statistical analysis

To examine the differences in clinical characteristics between breast cancer and control groups, we used the Student's t-test to analyze continuous variables and the chi-square test to analyze categorical variables. Conditional logistic regression analysis was applied to examine the effect of thyroid disorders, including hyperthyroidism, hypothyroidism, and acquired hypothyroidism, on the risk of developing breast cancer, and controlled for potential confounders. Logistic regression analysis was applied to examine the associations between treatments for hyperthyroidism or hypothyroidism and the risk of developing breast cancer in subgroup analysis. All statistical tests were two-sided, conducted at a significance level of 0.05, and reported using *p*-values and/or 95% confidence intervals (95% CI). All analyses were performed using Statistical Analytic System (SAS) software version 9.4 (SAS Institute, Cary, NC, USA).

203

204 **RESULTS**

205 A total of 103,466 patients were enrolled in our study, 51,733 in each group. As for
206 patient characteristics, the mean ages were 53.4 years and 53.3 years in the breast
207 cancer and control groups, respectively ($p=0.137$). In the breast cancer group, 36.9% of
208 the patients had ever used estrogen-containing medications; in the control group, 41.6%
209 of patients had ever used estrogen-containing medications ($p<0.001$). Prior to the time
210 of breast cancer diagnosis or the index date, 46 and 42 women received radioactive
211 iodine treatment in the breast cancer and control groups, respectively ($p=0.67$).
212 Significant differences in the proportions of thyroid disorders in the breast cancer group
213 and control group were found ($p=0.022$). There were 335 patients (0.7%) with
214 hypothyroidism in the breast cancer group and 291 patients (0.6%) in the control group.
215 A total of 1580 patients (3.1%) had the diagnosis of hyperthyroidism in the breast
216 cancer group and 1453 patients (2.8%) in the control group. (Table 1)

217

218

Table 1. Clinical characteristics of study subjects with and without breast cancer

Variable	Total (N=103,466)		Without breast cancer (N=51,733)		With breast cancer (N=51,733)		p value
	n	(%)	n	(%)	n	(%)	
Age, years (mean ± SD)	53.3±12.1		53.3±12.2		53.4±12.0		0.137 [†]
Gender							—

Female	103466	(100.0)	51733	(100.0)	51733	(100.0)	
Male	0	(0.0)	0	(0.0)	0	(0.0)	
Thyroid disorders							0.022
No	93675	(91.0)	46866	(91.0)	46809	(90.9)	
With Hypothyroidism	626	(0.6)	291	(0.6)	335	(0.7)	
With Hyperthyroidism	3033	(2.9)	1453	(2.8)	1580	(3.1)	
With Acquired Hypothyroidism	161	(0.2)	87	(0.2)	74	(0.1)	
Others	5462	(5.3)	2782	(5.4)	2680	(5.2)	
History of estrogen use							<0.001
No	62834	(60.7)	30197	(58.4)	32637	(63.1)	
Yes	40632	(39.3)	21536	(41.6)	19096	(36.9)	
History of radioactive iodine treatment							0.670
No	103378	(99.9)	51691	(99.9)	51687	(99.9)	
Yes	88	(0.1)	42	(0.1)	46	(0.1)	
Medication treatment for thyroid disorder							0.510
No	100569	(97.2)	50302	(97.2)	50267	(97.2)	
Yes	2897	(2.8)	1431	(2.8)	1466	(2.8)	
Thyroidectomy							0.330
No	102307	(98.9)	51137	(98.8)	51170	(98.9)	
Yes	1159	(1.1)	596	(1.2)	563	(1.1)	

+ T test; chi-squared test for all other *p-values*.

Acquired Hypothyroidism: with diagnoses of hyperthyroidism + hypothyroidism.

Both hyperthyroidism and hypothyroidism were associated with an increased risk of developing breast cancer after adjusting for age, estrogen-containing medication use, and a history of radioactive iodine treatment. Hyperthyroidism in all age groups showed an overall increased risk by 12% in breast cancer development (OR 1.12, 95% CI 1.04-

1
2
3 225 1.20, $p=0.003$), while hypothyroidism in all age groups had a 19% increased risk (OR
4
5 226 1.19, 95% CI 1.02-1.40, $p=0.029$). No significant change in risk was found among those
6
7 227 who had acquired hypothyroidism after treatment for hyperthyroidism (OR 0.88, 95% CI
8
9 228 0.64-1.22, $p=0.453$).
10
11
12
13 229
14
15
16 230 When we stratified by age group (age<45, age 45-55, age>55 years), patients with
17
18 231 hyperthyroidism aged 55 or under showed a significantly increased breast cancer risk;
19
20 232 this association disappeared in those aged 55 years and older. Among patients aged
21
22 233 <45 years, there was a 16% increased risk in breast cancer (OR 1.16, 95% CI 1.00-
23
24 234 1.34, $p=0.049$). In those aged 45-55 years there was a 15% increased risk (OR 1.15,
25
26 235 95% CI 1.02-1.29, $p=0.019$). The increased odds for breast cancer in patients with
27
28 236 hypothyroidism did not reach statistical significance among those 3 age groups. (Table
29
30 237 2)
31
32
33
34
35 238

Table 2. Adjusted odds ratio of breast cancer associated with thyroid disorders			
Variable	Adjusted OR	95% CI	p value
Overall			
Without Thyroid disorders	1.00	—	—
With Hypothyroidism	1.19	(1.02-1.40)	0.029
Without Thyroid disorders	1.00	—	—
With Hyperthyroidism	1.12	(1.04-1.20)	0.003
Without Thyroid disorders	1.00	—	—
With Acquired Hypothyroidism	0.88	(0.64-1.22)	0.453
Without Thyroid disorders	1.00	—	—
Others	0.99	(0.94-1.05)	0.806

Age < 45				
Without Thyroid disorders	1.00	—	—	
With Hypothyroidism	1.07	(0.71-1.60)	0.757	
Without Thyroid disorders	1.00	—	—	
With Hyperthyroidism	1.16	(1.00-1.34)	0.049	
Without Thyroid disorders	1.00	—	—	
With Acquired Hypothyroidism	0.62	(0.29-1.32)	0.214	
Without Thyroid disorders	1.00	—	—	
Others	1.03	(0.91-1.16)	0.692	
Age 45-55				
Without Thyroid disorders	1.00	—	—	
With Hypothyroidism	1.18	(0.90-1.54)	0.226	
Without Thyroid disorders	1.00	—	—	
With Hyperthyroidism	1.15	(1.02-1.29)	0.019	
Without Thyroid disorders	1.00	—	—	
With Acquired Hypothyroidism	0.84	(0.50-1.43)	0.532	
Without Thyroid disorders	1.00	—	—	
Others	1.05	(0.96-1.15)	0.276	
Age ≥ 56				
Without Thyroid disorders	1.00	—	—	
With Hypothyroidism	1.23	(0.98-1.54)	0.070	
Without Thyroid disorders	1.00	—	—	
With Hyperthyroidism	1.05	(0.93-1.19)	0.454	
Without Thyroid disorders	1.00	—	—	
With Acquired Hypothyroidism	1.07	(0.65-1.76)	0.792	
Without Thyroid disorders	1.00	—	—	
Others	0.92	(0.84-1.00)	0.052	

Adjusted OR was adjusted for age, estrogen use, and history of Iodine treatment by logistic regression analysis.

In the subgroup analysis, we examined whether medication and/or surgical treatment for hyper- or hypothyroidism would change the risk of having breast cancer. The

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

analysis showed no statistically significant differences between treatments for hyper- or hypothyroidism and the risk of developing breast cancer (OR 1.01, 95% CI 0.88-1.17, $p=0.857$; OR 0.80, 95% CI 0.54-1.18, $p=0.262$; respectively). (Table 3)

Table 3. Subgroup analysis for treatment - adjusted odds ratio of breast cancer associated with thyroid disorders (TD)

Variable	Adjusted OR	95% CI	p value
Subjects with Hypothyroidism			
Without TD medications	1.00	—	—
With TD medications ¹	0.80	(0.54-1.18)	0.262
Subjects with Hyperthyroidism			
Without TD medications and surgery	1.00	—	—
With TD medications ² or surgery ³	1.01	(0.88-1.17)	0.857
Subjects with Hyperthyroidism			
Without TD medications and surgery	1.00	—	—
With surgery ⁴	0.97	(0.74-1.27)	0.825
With TD medications	1.02	(0.88-1.19)	0.789

Adjusted OR was adjusted for age, estrogen use, and history of Iodine treatment by logistic regression analysis.

¹ Hypothyroidism medication: levothyroxine.
² Hyperthyroidism medications: methimazole, propylthiouracil (did not include radioactive iodine treatment since it was adjusted separately).
³ Surgery: thyroidectomy (partial or total).
⁴ If the patient received both medication and surgical treatment, the patient would be classified as surgical patient in this subgroup.

1
2
3 249 A separate analysis for autoimmune thyroid disease to examine the association with
4
5 250 breast cancer showed no statistical significance (OR 0.94, 95% CI 0.68-1.29, $p=0.685$
6
7
8 251 for Hashimoto; OR 1.20, 95% CI 0.96-1.50, $p=0.109$ for Graves'). We also performed an
9
10 252 additional analysis with the exclusion of those who only had a 'one-time' diagnosis of
11
12 253 thyroid disorder during an inpatient admission to eliminate possible inpatient admission
13
14 254 bias. In the breast cancer group, there were 22 patients with only one-time
15
16 255 hypothyroidism diagnosis and 77 patients with only one-time hyperthyroidism diagnosis
17
18 256 out of 335 and 1580 patients respectively; while in the control group, 17 patients with
19
20 257 only one-time hypothyroidism diagnosis out of 291 and 82 patients with only one-time
21
22 258 hyperthyroidism diagnosis out of 1453 patients. After excluding those with only one-time
23
24 259 diagnosis of hyperthyroidism or hypothyroidism, the results showed similar associations
25
26 260 as above. Hyperthyroidism in all age groups showed an overall increased risk by 13% in
27
28 261 breast cancer development (adjusted OR 1.13, 95% CI 1.05-1.21, $p=0.002$), while
29
30 262 hypothyroidism in all age groups had an 18% increased risk (adjusted OR 1.18, 95% CI
31
32 263 1.01-1.39, $p=0.043$).
33
34
35
36
37
38
39 264
40
41
42 265
43
44
45
46 266
47
48
49 267
50
51
52 268
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

269
270
271 **DISCUSSION**

272 This is the first study in an Asian population assessing the association between
273 hyperthyroidism, hypothyroidism and breast cancer. Among a total of 103,466 women in
274 our study, we found increased risks of developing breast cancer in patients with medical
275 history of either hyperthyroidism or hypothyroidism despite treatment. The association is
276 significant in patients under age 55 years old with hyperthyroidism.

277
278 Since Beaston first described using thyroid extract to treat metastatic breast cancer in
279 the Lancet in 1896, many studies have investigated the relationship between thyroid
280 hormone and cancers.^{20 21} Specific alterations of thyroid hormone receptors (TR) have
281 been found in different types of carcinomas, including breast cancer, and many studies
282 observed associations between the expression of TRs and the regulation of
283 oncogenes.²¹⁻²³ Several physiological similarities have been discovered between the
284 thyroid gland and mammary gland. For one, both thyroid follicular cells and breast
285 lactating cells store iodine through natrium-iodine symporter (NIS)-mediated iodine
286 uptake.²⁴⁻²⁷ The oxidization of iodine in the alveolar mammary cells utilizes
287 lactohydroperoxidase, which is mechanistically similar to peroxidase in thyroid glands.²⁸

Several *in vitro* studies have shown that high levels of thyroid hormones may possess estrogen-like effects and may promote breast cancer proliferation and angiogenesis.^{5 13}

^{21 23 29} It has also been shown that the activation of TR in mammary glands may induce the differentiation and lobular growth of breast tissues, an effect similar to that seen with estrogen.^{21 22} Active triiodothyronine (T3) has been found to promote breast cancer cell proliferation and to increase the effect of 17beta-estradiol (E2)-mediated cell proliferation in some breast cancer cell lines.¹³ In population-based studies, T3 levels have also been found to have a positive correlation with breast cancer tumor size and the risk of lymph node metastasis.³⁰

Hypothyroidism may trigger hypersensitization of mammary glandular epithelium to estrogen and prolactin, possibly related to low circulating thyroid hormone, and further lead to mammary dysplasia and neoplasia of the breast.^{17 18 31} Previous studies showed a positive correlation between elevated serum prolactin level and an increased risk of breast cancer,^{32 33} while other study also found that mild hyperprolactinemia did not carry significant health risks and thus treatment was not required in post-menopausal women.³⁴ The existence of a genetic predisposition for hypothyroidism and breast cancer has been hypothesized as well.^{6 10}

We did not find a statistically significant association between autoimmune thyroid disease (AITD) and breast cancer risk in this study. However, several studies have shown that there may be a possible association between AITD and breast cancer, but

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

311 controversial in AITD and breast cancer survival. A study by Jiskra *et al.* found a higher
312 prevalence of euthyroid AITD in women with breast cancer and no prognostic impact
313 from AITD on breast cancer survival.³⁵

314

315 In our study, the significantly increased risk of breast cancer among patients with the
316 diagnosis of hyperthyroidism under 55 years of age is possibly related to higher levels
317 of thyroid hormone in addition to the physiological level of estrogen. The increased risk
318 drops from 15-16% to 5% with no statistical significance in hyperthyroidism patients >55
319 years of age. This is likely related to the menopausal status of these patients, an
320 indicator of low estrogen levels. In the further subgroup analysis, we found that
321 hyperthyroidism treatment with medications and/or surgery and thyroid replacement
322 treatment for hypothyroidism did not alter the risk of having breast cancer in the future.
323 While there is a 19% increased risk of breast cancer in hypothyroidism patients, the
324 statistical significance disappears when we stratify these patients into the 3 age groups.
325 Since there were only 335 patients with a diagnosis of hypothyroidism who developed
326 breast cancer, dividing this group into 3 age cohorts led to a decrease in power. Based
327 on our overall results, however, we can hypothesize that there is no protective effect of
328 hypothyroidism in the development of breast cancer. Interestingly, the use of estrogen-
329 containing products (which we controlled for) was not a contributing factor to an
330 increased risk of breast cancer in this study.

In 2017, it is estimated that 40,610 women may die of breast cancer in the U.S.¹ Current breast cancer screening guidelines published by the U.S. Preventive Services Task Force (USPSTF) recommend biennial screening mammography for women at average risk aged 50 to 74 years.³⁶ The American Cancer Society (ACS) recommends annual screening mammography for women at average risk aged 45 to 55 years then biennial screening after 55 years of age.³⁷ Our nationwide population-based study showed a significantly increased breast cancer risk in Asian women with medical history of hyperthyroidism under the age of 55 years and an increased risk or at least no protective effect of hypothyroidism. More studies are needed to examine this association in different age groups.

Limitations

The findings from our study were derived from a large population-based dataset; this minimized selection bias. The case-control study design using an administrative claims database reduced the recall bias; however, the findings might be less accurate due to the lack of supporting laboratory data; this includes thyroid antibody, TSH and thyroid hormones levels as well as breast cancer stages and receptor status. In order to minimize bias, we only studied those with a diagnosis of hyper- or hypothyroidism who were documented as having these diagnoses in at least three outpatient visits or one inpatient admission. All breast cancer patients in this study had the diagnosis of breast cancer and possessed the certificate of catastrophic illness. To avoid false claims, the National Health Insurance Bureau (NHIB) randomly samples a fixed percentage of claims from each hospital every year to confirm diagnosis validity, and medical records

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

were independently reviewed by professional experts. Since this study is based on administrative claims, the results may be underestimated or overestimated, as only patients who seek medical attention were evaluated and treated. Since thyroid disorders are often chronic diseases rather than acute onset, we thought that it might not be as useful to adjust the time lapse from the diagnosis of thyroid disorder to breast cancer.

Conclusion

Our nationwide Asian population-based study suggests that Asian women under the age of 55 years with medical history of hyperthyroidism have a significantly increased risk of developing breast cancer regardless of treatment. Women with a history of hypothyroidism may also have an increased risk. Further studies are needed to assess the association between age, hypothyroidism, and breast cancer risk.

373

374

375

376

377 **Author contributions:**

378 **Concept of study:** C-H Weng and T-H Lin

379 **Study design:** C-H Weng, X Luo, C-H Lin and T-H Lin

380 **Statistical analysis:** Y-H Chen and C-H Lin

381 **Interpretation of results:** C-H Weng, Y-H Chen, X Luo, and C-H Lin

382 **Manuscript writing:** C-H Weng

383 The other authors provided inputs, expertise, and critical review of the manuscript.

384 **C-H Weng and T-H Lin contributed as co-senior authors to this article.**

385

386

387

388

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

389

390

391

392

393 **Acknowledgements**

394 Special thanks to Professor & Chair Martha A. Zeiger, MD, FACS, FACE, Department of

395 Surgery, University of Virginia, Professor Christopher B. Umbricht, MD, PhD,

396 Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore,

397 MD, and Dr. Erin R. Okawa, MD, Boston Childrens Hospital Division of Endocrinology,

398 Boston, MA, for reviewing the manuscript and their comments.

399 The preliminary results from this study have been presented in part at the 86th Annual

400 Meeting of the American Thyroid Association in Denver, CO by Chien-Hsiang Weng,

401 MD, MPH, September 21-25, 2016. Authors thank all the comments and advices from

402 the conference.

403 This study has been approved by the Institutional Review Board of Taichung Veterans

404 General Hospital, Taichung, Taiwan (IRB # CE13151B-3). The study is based in part on

405 data from the National Health Insurance Research Database provided by the Bureau of

406 National Health Insurance, Department of Health and managed by National Health

407 Research Institutes. The interpretation and conclusions contained herein do not

represent those of National Health Insurance Administration, Department of Health or National Health Research Institutes.

Declaration of interest: The authors declare no potential conflicts of interest.

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Data sharing: Extra data is available by emailing the Corresponding author (jth.lin@gmail.com).

References

1. U.S. Breast Cancer Statistics. http://www.breastcancer.org/symptoms/understand_bc/statistics 2017
2. American Thyroid Association. <http://www.thyroid.org/media-main/about-hypothyroidism/> 2017
3. SEER Stat Fact Sheets: Female Breast Cancer, 2017.
4. Khan SR, Chaker L, Ruiter R, et al. Thyroid Function and Cancer Risk: The Rotterdam Study. *J Clin Endocrinol Metab* 2016;101(12):5030-36. doi: 10.1210/jc.2016-2104

1
2
3 426 5. Sogaard M, Farkas DK, Ehrenstein V, et al. Hypothyroidism and hyperthyroidism and breast
4
5
6 427 cancer risk: a nationwide cohort study. *Eur J Endocrinol* 2016;174(4):409-14. doi:
7
8 428 10.1530/EJE-15-0989
9
10
11 429 6. Kuijpers JL, Nyklictek I, Louwman MW, et al. Hypothyroidism might be related to breast
12
13 430 cancer in post-menopausal women. *Thyroid* 2005;15(11):1253-9. doi:
14
15 431 10.1089/thy.2005.15.1253
16
17
18 432 7. Angelousi AG, Anagnostou VK, Stamatakos MK, et al. Mechanisms in endocrinology: primary
19
20 433 HT and risk for breast cancer: a systematic review and meta-analysis. *Eur J Endocrinol*
21
22 434 2012;166(3):373-81. doi: 10.1530/EJE-11-0838
23
24
25 435 8. Tseng FY, Lin WY, Li CI, et al. Subclinical hypothyroidism is associated with increased risk for
26
27 436 cancer mortality in adult Taiwanese-a 10 years population-based cohort. *PLoS One*
28
29 437 2015;10(4):e0122955. doi: 10.1371/journal.pone.0122955
30
31
32 438 9. Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. *Cancer*
33
34 439 *Res* 1990;50(8):2283-9.
35
36
37 440 10. Smyth PP. The thyroid and breast cancer: a significant association? *Ann Med*
38
39 441 1997;29(3):189-91.
40
41
42 442 11. Morabia A, Szklo M, Stewart W, et al. Thyroid hormones and duration of ovulatory activity
43
44 443 in the etiology of breast cancer. *Cancer Epidemiol Biomarkers Prev* 1992;1(5):389-93.
45
46
47 444 12. Tosovic A, Bondeson AG, Bondeson L, et al. Prospectively measured triiodothyronine levels
48
49 445 are positively associated with breast cancer risk in postmenopausal women. *Breast*
50
51 446 *Cancer Res* 2010;12(3):R33. doi: 10.1186/bcr2587
52
53
54
55
56
57
58
59
60

- 1
2
3 447 13. Hall LC, Salazar EP, Kane SR, et al. Effects of thyroid hormones on human breast cancer cell
4
5 proliferation. *J Steroid Biochem Mol Biol* 2008;109(1-2):57-66. doi:
6 448
7 10.1016/j.jsbmb.2007.12.008
8 449
9
10 450 14. Moeller LC, Fuhrer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical
11
12 perspective. *Endocr Relat Cancer* 2013;20(2):R19-29. doi: 10.1530/ERC-12-0219
13 451
14
15 452 15. Smith GL, Smith BD, Giordano SH, et al. Risk of hypothyroidism in older breast cancer
16
17 patients treated with radiation. *Cancer* 2008;112(6):1371-9. doi: 10.1002/cncr.23307
18 453
19 [published Online First: 2008/01/24]
20 454
21
22 455 16. Khan NF, Mant D, Carpenter L, et al. Long-term health outcomes in a British cohort of breast,
23
24 colorectal and prostate cancer survivors: a database study. *Br J Cancer* 2011;105 Suppl
25 456
26 1:S29-37. doi: 10.1038/bjc.2011.420 [published Online First: 2011/11/09]
27 457
28
29 458 17. Mitra I. Mammatropic effect of prolactin enhanced by thyroidectomy. *Nature*
30
31 1974;248:525. doi: 10.1038/248525a0
32 459
33
34 460 18. Vorherr H. Thyroid disease in relation to breast cancer. *Klin Wochenschr* 1978;56(23):1139-
35
36 45.
37 461
38
39 462 19. Fang Y, Yao L, Sun J, et al. Does thyroid dysfunction increase the risk of breast cancer? A
40
41 systematic review and meta-analysis. *J Endocrinol Invest* 2017 doi: 10.1007/s40618-017-
42 463
43 0679-x
44 464
45
46 465 20. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions
47
48 for a new method of treatment, with illustrative cases. *The Lancet* 1896;148(3803):162-
49 466
50 65. doi: 10.1016/S0140-6736(01)72384-7
51 467
52
53
54
55
56
57
58
59
60

1
2
3 468 21. Conde I, Paniagua R, Zamora J, et al. Influence of thyroid hormone receptors on breast
4
5
6 469 cancer cell proliferation. *Ann Oncol* 2006;17(1):60-4. doi: 10.1093/annonc/mdj040
7
8 470 22. Gonzalez-Sancho JM, Garcia V, Bonilla F, et al. Thyroid hormone receptors/THR genes in
9
10 471 human cancer. *Cancer Lett* 2003;192(2):121-32.
12
13 472 23. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation
14
15 473 of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. *Oncogene*
16
17 474 2002;21(5):761-8. doi: 10.1038/sj.onc.1205136
19
20 475 24. Smyth PP, Shering SG, Kilbane MT, et al. Serum thyroid peroxidase autoantibodies, thyroid
21
22 476 volume, and outcome in breast carcinoma. *J Clin Endocrinol Metab* 1998;83(8):2711-6.
23
24 477 doi: 10.1210/jcem.83.8.5049
26
27 478 25. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter.
28
29 479 *Nature* 1996;379(6564):458-60. doi: 10.1038/379458a0
31
32 480 26. Chung JK. Sodium iodide symporter: its role in nuclear medicine. *J Nucl Med*
33
34 481 2002;43(9):1188-200.
36
37 482 27. Turken O, NarIn Y, DemIrbas S, et al. Breast cancer in association with thyroid disorders.
38
39 483 *Breast Cancer Res* 2003;5(5):R110-3. doi: 10.1186/bcr609
41
42 484 28. Fierabracci P, Pinchera A, Campani D, et al. Association between breast cancer and
43
44 485 autoimmune thyroid disorders: no increase of lymphocytic infiltrates in breast
45
46 486 malignant tissues. *J Endocrinol Invest* 2006;29(3):248-51. doi: 10.1007/BF03345548
48
49 487 29. Nogueira CR, Brentani MM. Triiodothyronine mimics the effects of estrogen in breast cancer
50
51 488 cell lines. *J Steroid Biochem Mol Biol* 1996;59(3-4):271-9.
53
54
55
56
57
58
59
60

- 489 30. Tosovic A, Bondeson AG, Bondeson L, et al. T3 levels in relation to prognostic factors in
490 breast cancer: a population-based prospective cohort study. *BMC Cancer* 2014;14:536.
491 doi: 10.1186/1471-2407-14-536
- 492 31. Kwa HG, van der Gugten AA, Sala M, et al. Effect of pituitary tumours and grafts on plasma
493 prolactin levels. *Eur J Cancer* 1972;8(1):39-54. [published Online First: 1972/02/01]
- 494 32. Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women.
495 *Breast Dis* 2005;24:3-15. [published Online First: 2006/08/19]
- 496 33. Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. *Cancer Lett* 2006;243(2):160-9.
497 doi: 10.1016/j.canlet.2006.01.032 [published Online First: 2006/03/15]
- 498 34. Schlechte JA. Clinical practice. Prolactinoma. *N Engl J Med* 2003;349(21):2035-41. doi:
499 10.1056/NEJMcp025334 [published Online First: 2003/11/25]
- 500 35. Jiskra J, Barkmanova J, Limanova Z, et al. Thyroid autoimmunity occurs more frequently in
501 women with breast cancer compared to women with colorectal cancer and controls but
502 it has no impact on relapse-free and overall survival. *Oncol Rep* 2007;18(6):1603-11.
503 [published Online First: 2007/11/06]
- 504 36. Siu AL, Force USPST. Screening for Breast Cancer: U.S. Preventive Services Task Force
505 Recommendation Statement. *Ann Intern Med* 2016;164(4):279-96. doi: 10.7326/M15-
506 2886
- 507 37. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average
508 Risk: 2015 Guideline Update From the American Cancer Society. *JAMA*
509 2015;314(15):1599-614. doi: 10.1001/jama.2015.12783

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legend:

Figure 1. Flow Diagram of Participants Selection and Study Design

12x4mm (600 x 600 DPI)

bmjopen-2017-020194 on 30 March 2018. Downloaded from <http://bmjopen.bmj.com/> on April 9, 2024 by guest. Protected by copyright.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	3	Nationwide population-based study
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3	Findings and Interpretation
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5	Paragraph 1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	5	Paragraph 3
Methods				
Study design	4	Present key elements of study design early in the paper		Paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection		Paragraph 1
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	8	Breast cancer Case-control match Hyperthyroidism and hypothyroidism
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case	8	Case-control match
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7	
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7	NHIRD & RCIPT & LHID Hyper-/hypothyroidism, breast cancer
Bias	9	Describe any efforts to address potential sources of bias	2	Limitations of study

Study size	10	Explain how the study size was arrived at	84	51,733 patients in each group
------------	----	---	----	-------------------------------

For peer review only

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10	Statistical analysis paragraph
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10	
		(b) Describe any methods used to examine subgroups and interactions	10	
		(c) Explain how missing data were addressed	N/A	
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	8-9	Case-control match paragraph
		Case-control study—If applicable, explain how matching of cases and controls was addressed		
		Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy		
		(e) Describe any sensitivity analyses	N/A	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7-9 & Fig 1	
		(b) Give reasons for non-participation at each stage	7-9 & Fig 1	
		(c) Consider use of a flow diagram	Fig	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11	Paragraph 1 and Table 1
		(b) Indicate number of participants with missing data for each variable of interest	N/A	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	N/A	
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	N/A	
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	12-16	
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12-16	
		(b) Report category boundaries when continuous variables were categorized	12-16	Paragraphs and Table 2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14-16 and Table	
Discussion				
Key results	18	Summarise key results with reference to study objectives	17	Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-22	Paragraph 2-6
Generalisability	21	Discuss the generalisability (external validity) of the study results	19-22	
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23	Acknowledgement

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Thyroid Disorders and Breast Cancer Risk in Asian Population: A Nationwide Population-Based Case-Control Study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020194.R2
Article Type:	Research
Date Submitted by the Author:	09-Jan-2018
Complete List of Authors:	Weng, Chien-Hsiang; Brown University Warren Alpert Medical School, Family Medicine Chen, Yi-Huei ; Taichung Veterans General Hospital, Medical Research Lin, Ching-Heng ; Taichung Veterans General Hospital, Medical Research Luo, Xun; Johns Hopkins School of Medicine, Surgery Lin, Tseng-Hsi ; Taichung Veterans General Hospital, Pathology and Laboratory Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Oncology, Public health
Keywords:	Thyroid disease < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Breast tumours < ONCOLOGY, PREVENTIVE MEDICINE

SCHOLARONE™
Manuscripts

Only

1

2

3 1 **Thyroid Disorders and Breast Cancer Risk in Asian Population:**

4

5

6 2 **A Nationwide Population-Based Case-Control Study in Taiwan**

7

8

9 3

10

11

12 4 Chien-Hsiang Weng^{1,2,3,†}, Yi-Huei Chen⁴, Ching-Heng Lin⁴,

13

14 5 Xun Luo³, Tseng-Hsi Lin^{5,6,†}

15

16 6

17

18

19 7 ¹ Department of Family Medicine, Brown University Warren Alpert Medical School.

20

21 8 Pawtucket, RI 02860, USA

22

23

24 9 ² NH Dartmouth Family Medicine Residency, Concord Hospital. Concord, NH 03301,

25

26 10 USA

27

28

29 11 ³ Department of Surgery, Johns Hopkins University School of Medicine. Baltimore, MD

30

31 12 21205, USA

32

33

34 13 ⁴ Department of Medical Research, Taichung Veterans General Hospital. Taichung

35

36 14 40705, TAIWAN

37

38

39 15 ⁵ Division of Hematology/Oncology, Department of Internal Medicine, Taichung Veterans

40

41 16 General Hospital. Taichung 40705, TAIWAN

42

43

44

45 17 ⁶ Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine,

46

47 18 Taichung Veterans General Hospital. Taichung 40705, TAIWAN

48

49

50 19 [†] Chien-Hsiang Weng and Tseng-Hsi Lin contributed as co-senior authors to this article.

51

21

Key words: hyperthyroidism; hypothyroidism; breast cancer; cancer risk

23

Corresponding to:

Tseng-Hsi Lin, MD, PhD

Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine

Taichung Veterans General Hospital, Taichung, Taiwan

Address: 1650 Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan

Telephone: +886-4-23592525 ext. 3380

Fax: +886-4-23559018

E-mail: jth.lin@gmail.com

32

33

34

Word count: 2714

36

37

38

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To evaluate whether hyper- or hypothyroidism increases the risk of subsequent breast cancer in an Asian population.

Design: Nationwide population-based case-control study.

Setting: All health care facilities in Taiwan.

Participants: A total of 103,466 women (mean age 53.3 years) were enrolled.

Methods: 51,733 adult women with newly diagnosed with primary breast cancer without a previous cancer history between 2006 and 2011 were identified and included in our study. 51,733 women with no cancer diagnosis prior to the index date were age-matched as controls. Diagnosis of hyper- or hypothyroidism prior to the diagnosis of breast cancer or the same index date was identified, age, histories of thyroid disease treatment, estrogen use and radioactive-iodine treatment were adjusted.

Main outcome measures: To identify risk differences in developing breast cancer among patients with a medical history of hyper- or hypothyroidism.

Results: There was a significantly increased risk of breast cancer in women with hyperthyroidism under age of 55 years (age <45: OR 1.16, p=0.049; age 45-55: OR 1.15, p=0.019). Patients with hypothyroidism also showed an increased risk of breast cancer (OR 1.19, p=0.029) without statistical significance after stratification by age group (age <45, 45-55, >55 years). Treatment for thyroid disorders did not alter the association in subgroup analyses (p=0.857; 0.262 respectively).

Conclusions: Asian women under 55 years of age with history of hyperthyroidism have a significantly increased risk of breast cancer regardless of treatment. Women with history of hypothyroidism may also have an increased risk.

Strengths and limitations of this study

- This is the first study in an Asian population assessing the association between hyperthyroidism, hypothyroidism, breast cancer, and age.
- The main strength of this study is the large population-based dataset which minimized the selection bias.
- The most important limitation of this study is the characteristic of the database. Since it is a national health insurance claims database, detailed TSH, T4, T3 level, types and stages of breast cancer are not available for further stratification and analysis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

79 **INTRODUCTION**

80 One in eight women will develop breast cancer in their lifetime, a disease prevalence
81 similar to the risk of thyroid disorders in this population.¹⁻³ Since high thyroid hormone
82 levels are found to have estrogen-like effects in several *in vitro* studies, thyroid hormone
83 levels and their relation to the development of breast and other cancers have been
84 studied in the past with conflicting results and primarily in Caucasian populations. Most
85 of the literature published to date have relied on studies of relatively small sample
86 sizes.⁴⁻¹⁴ Sogaard *et al.* published a large study in 2016 utilizing the national registry in
87 Denmark found an increased risk of breast cancer in those who had a medical history of
88 hyperthyroidism without age stratification.⁵

90 Previous observational studies also showed a higher prevalence of hypothyroidism in
91 patients with breast cancer.^{15 16} Older studies proposed that hypothyroidism may induce
92 the breast epithelial cells' sensitivity to prolactin and estrogen.^{17 18} A recent systematic
93 review and meta-analysis included 13 population-based studies with a total of 24,808
94 participants through June 2016 found that either hypothyroidism or hyperthyroidism has
95 no related risk for breast cancer.¹⁹

97 We conducted the first study in an Asian population In order to assess the association
98 between hyperthyroidism, hypothyroidism and breast cancer in different age groups. It
99 is a nationwide population-based case-control study utilizing the Taiwanese National
100 Health Insurance Research Database (NHIRD), one of the largest administrative health

care databases in the world; our aim was to discover the relationship between hyper- or
hypothyroidism and breast cancer from the epidemiological aspect.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

119 **METHODS**

120 We designed a case-control study utilizing the Taiwanese National Health Insurance
121 Research Database (NHIRD). Female patients with a new diagnosis of primary breast
122 cancer and no previous cancer history were identified from the NHIRD (diagnosed
123 between 2006 and 2011). Age-matched female individuals without a breast cancer
124 diagnosis were randomly selected as controls. We then identified the status of thyroid
125 disorders prior to the diagnosis of breast cancer in the case group or the same index
126 date in the control group. We excluded those with a history of a thyroid malignancy.
127 (Figure 1)

129 **Taiwanese National Health Insurance Research Database (NHIRD)**

130 The National Health Insurance program was established in Taiwan in March 1995 and
131 covers about 99% of the Taiwanese population. The National Health Insurance
132 Research Database (NHIRD), established by the National Health Research Institute
133 (NHRI), is a claims database maintained by the Department of Health and the NHRI.
134 There are several subset databases in the NHIRD including the Registry for
135 Catastrophic Illness Patient Database (RCIPD). Breast cancer is defined as a
136 catastrophic illness by the government. Thus, when patients are diagnosed with breast
137 cancer, they will apply and register for the certificate of catastrophic illness.

The Longitudinal Health Insurance Database (LHID) is a database of one million randomly selected insurers from the NHIRD. We used the 2010 version of the LHID which included 1,000,000 individuals randomly selected from the total of 23,251,700 insured.

Breast cancer

In order to identify patients with newly diagnosed primary breast cancer, we searched the NHIRD by using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD9-CM) code 174 and 175, cross-linking these to the RCIPD. The identified patients all had newly diagnosed breast cancer between 2006 and 2011 and possessed a certificate of catastrophic illness. There were 53,488 total patients identified.

We then excluded male gender, age unknown, sex unknown, or age < 18 or >120 years old at the time of diagnosis. We excluded patients with diagnoses of other malignant diseases before the diagnosis of breast cancer. A total of 51,733 patients were identified from the NHIRD by the above criteria as cases.

Case-control match

We applied a one-to-one match for the control group, randomly matched for age, sex, and the same index date (the month and year of breast cancer diagnosis in the case group) from the LHID. We excluded male gender, age unknown, sex unknown, age < 18

or >120 years old at time of index date, or deceased before index date. We excluded patients with the diagnosis of breast cancer. Also excluded patients were those with diagnoses of other malignant diseases before the index date. A total of 51,733 women were selected as controls.

Hyperthyroidism and hypothyroidism

To identify patients with the diagnosis of hyperthyroidism, we used the ICD9-CM code 242 with additional criteria including the same diagnosis in at least three outpatient visits or one inpatient admission. We stipulated that the first diagnosis of hyperthyroidism had to occur before the date of first breast cancer diagnosis in the case group or the index date in the control group. We used the ICD9-CM codes 243 and 244 with the same additional criteria to identify patients with hypothyroidism. We also excluded patients with ICD9-CM codes 244.0, 244.1, 244.2, 244.3 in the hypothyroidism group since those are acquired hypothyroidism. We identified a specific group of patients with both hyperthyroidism (ICD9-CM 242) and hypothyroidism diagnoses (ICD9-CM 244.0, 244.1, 244.2, 244.3), which represents acquired hypothyroidism from hyperthyroidism treatments. We excluded those with a diagnosis of thyroid malignancy in our study since strong evidences have shown an increased risk of developing breast cancer among thyroid cancer survivors.²⁰

Other adjustments

We adjusted for estrogen use or hormone replacement therapy, a history of radioactive iodine treatment, medication or surgical treatment for thyroid disease, and age. We identified the use of hyperthyroidism, hypothyroidism medications, estrogen-containing products including oral forms, injection forms, or external-use forms available on the market in Taiwan, and labeled them as ever-used versus never-used. We did not calculate the length of use in each female since it is very difficult to know their compliance and effects between different products. We also identified females who have ever received radioactive iodine treatment and adjusted it in our analysis.

Statistical analysis

To examine the differences in clinical characteristics between breast cancer and control groups, we used the Student's t-test to analyze continuous variables and the chi-square test to analyze categorical variables. Conditional logistic regression analysis was applied to examine the effect of thyroid disorders, including hyperthyroidism, hypothyroidism, and acquired hypothyroidism, on the risk of developing breast cancer, and controlled for potential confounders. Logistic regression analysis was applied to examine the associations between treatments for hyperthyroidism or hypothyroidism and the risk of developing breast cancer in subgroup analysis. All statistical tests were two-sided, conducted at a significance level of 0.05, and reported using *p*-values and/or 95% confidence intervals (95% CI). All analyses were performed using Statistical Analytic System (SAS) software version 9.4 (SAS Institute, Cary, NC, USA).

RESULTS

A total of 103,466 patients were enrolled in our study, 51,733 in each group. As for patient characteristics, the mean ages were 53.4 years and 53.3 years in the breast cancer and control groups, respectively ($p=0.137$). In the breast cancer group, 36.9% of the patients had ever used estrogen-containing medications; in the control group, 41.6% of patients had ever used estrogen-containing medications ($p<0.001$). Prior to the time of breast cancer diagnosis or the index date, 46 and 42 women received radioactive iodine treatment in the breast cancer and control groups, respectively ($p=0.67$). Significant differences in the proportions of thyroid disorders in the breast cancer group and control group were found ($p=0.022$). There were 335 patients (0.7%) with hypothyroidism in the breast cancer group and 291 patients (0.6%) in the control group. A total of 1580 patients (3.1%) had the diagnosis of hyperthyroidism in the breast cancer group and 1453 patients (2.8%) in the control group. (Table 1)

Table 1. Clinical characteristics of study subjects with and without breast cancer

Variable	Total (N=103,466)		Without breast cancer (N=51,733)		With breast cancer (N=51,733)		p value
	n	(%)	n	(%)	n	(%)	

Age, years (mean ± SD)	53.3±12.1 53.3±12.2 53.4±12.0						0.137 ⁺
Gender							—
Female	103466	(100.0)	51733	(100.0)	51733	(100.0)	
Male	0	(0.0)	0	(0.0)	0	(0.0)	
Thyroid disorders							0.022
No	93675	(91.0)	46866	(91.0)	46809	(90.9)	
With Hypothyroidism	626	(0.6)	291	(0.6)	335	(0.7)	
With Hyperthyroidism	3033	(2.9)	1453	(2.8)	1580	(3.1)	
With Acquired Hypothyroidism	161	(0.2)	87	(0.2)	74	(0.1)	
Others	5462	(5.3)	2782	(5.4)	2680	(5.2)	
History of estrogen use							<0.001
No	62834	(60.7)	30197	(58.4)	32637	(63.1)	
Yes	40632	(39.3)	21536	(41.6)	19096	(36.9)	
History of radioactive iodine treatment							0.670
No	103378	(99.9)	51691	(99.9)	51687	(99.9)	
Yes	88	(0.1)	42	(0.1)	46	(0.1)	
Medication treatment for thyroid disorder							0.510
No	100569	(97.2)	50302	(97.2)	50267	(97.2)	
Yes	2897	(2.8)	1431	(2.8)	1466	(2.8)	
Thyroidectomy							0.330
No	102307	(98.9)	51137	(98.8)	51170	(98.9)	
Yes	1159	(1.1)	596	(1.2)	563	(1.1)	

⁺ T test; chi-squared test for all other *p-values*.

Acquired Hypothyroidism: with diagnoses of hyperthyroidism + hypothyroidism.

Both hyperthyroidism and hypothyroidism were associated with an increased risk of developing breast cancer after adjusting for age, estrogen-containing medication use,

224 and a history of radioactive iodine treatment. Hyperthyroidism in all age groups showed
225 an overall increased risk by 12% in breast cancer development (OR 1.12, 95% CI 1.04-
226 1.20, $p=0.003$), while hypothyroidism in all age groups had a 19% increased risk (OR
227 1.19, 95% CI 1.02-1.40, $p=0.029$). No significant change in risk was found among those
228 who had acquired hypothyroidism after treatment for hyperthyroidism (OR 0.88, 95% CI
229 0.64-1.22, $p=0.453$).

231 When we stratified by age group (age<45, age 45-55, age>55 years), patients with
232 hyperthyroidism aged 55 or under showed a significantly increased breast cancer risk;
233 this association disappeared in those aged 55 years and older. Among patients aged
234 <45 years, there was a 16% increased risk in breast cancer (OR 1.16, 95% CI 1.00-
235 1.34, $p=0.049$). In those aged 45-55 years there was a 15% increased risk (OR 1.15,
236 95% CI 1.02-1.29, $p=0.019$). The increased odds for breast cancer in patients with
237 hypothyroidism did not reach statistical significance among those 3 age groups. (Table
238 2)

Table 2. Adjusted odds ratio of breast cancer associated with thyroid disorders

Variable	Adjusted OR	95% CI	<i>p</i> value
Overall			
Without Thyroid disorders	1.00	—	—
With Hypothyroidism	1.19	(1.02-1.40)	0.029
Without Thyroid disorders	1.00	—	—
With Hyperthyroidism	1.12	(1.04-1.20)	0.003
Without Thyroid disorders	1.00	—	—

With Acquired Hypothyroidism	0.88	(0.64-1.22)	0.453
Without Thyroid disorders	1.00	—	—
Others	0.99	(0.94-1.05)	0.806
Age < 45			
Without Thyroid disorders	1.00	—	—
With Hypothyroidism	1.07	(0.71-1.60)	0.757
Without Thyroid disorders	1.00	—	—
With Hyperthyroidism	1.16	(1.00-1.34)	0.049
Without Thyroid disorders	1.00	—	—
With Acquired Hypothyroidism	0.62	(0.29-1.32)	0.214
Without Thyroid disorders	1.00	—	—
Others	1.03	(0.91-1.16)	0.692
Age 45-55			
Without Thyroid disorders	1.00	—	—
With Hypothyroidism	1.18	(0.90-1.54)	0.226
Without Thyroid disorders	1.00	—	—
With Hyperthyroidism	1.15	(1.02-1.29)	0.019
Without Thyroid disorders	1.00	—	—
With Acquired Hypothyroidism	0.84	(0.50-1.43)	0.532
Without Thyroid disorders	1.00	—	—
Others	1.05	(0.96-1.15)	0.276
Age ≥ 56			
Without Thyroid disorders	1.00	—	—
With Hypothyroidism	1.23	(0.98-1.54)	0.070
Without Thyroid disorders	1.00	—	—
With Hyperthyroidism	1.05	(0.93-1.19)	0.454
Without Thyroid disorders	1.00	—	—
With Acquired Hypothyroidism	1.07	(0.65-1.76)	0.792
Without Thyroid disorders	1.00	—	—
Others	0.92	(0.84-1.00)	0.052

Adjusted OR was adjusted for age, estrogen use, and history of Iodine treatment by logistic regression analysis.

In the subgroup analysis, we examined whether medication and/or surgical treatment for hyper- or hypothyroidism would change the risk of having breast cancer. The analysis showed no statistically significant differences between treatments for hyper- or hypothyroidism and the risk of developing breast cancer (OR 1.01, 95% CI 0.88-1.17, $p=0.857$; OR 0.80, 95% CI 0.54-1.18, $p=0.262$; respectively). (Table 3)

Table 3. Subgroup analysis for treatment - adjusted odds ratio of breast cancer associated with thyroid disorders (TD)

Variable	Adjusted OR	95% CI	<i>p</i> value
Subjects with Hypothyroidism			
Without TD medications	1.00	—	—
With TD medications ¹	0.80	(0.54-1.18)	0.262
Subjects with Hyperthyroidism			
Without TD medications and surgery	1.00	—	—
With TD medications ² or surgery ³	1.01	(0.88-1.17)	0.857
Subjects with Hyperthyroidism			
Without TD medications and surgery	1.00	—	—
With surgery ⁴	0.97	(0.74-1.27)	0.825
With TD medications	1.02	(0.88-1.19)	0.789

Adjusted OR was adjusted for age, estrogen use, and history of iodine treatment by logistic regression analysis.

¹ Hypothyroidism medication: levothyroxine.
² Hyperthyroidism medications: methimazole, propylthiouracil (did not include radioactive iodine treatment since it was adjusted separately).
³ Surgery: thyroidectomy (partial or total).
⁴ If the patient received both medication and surgical treatment, the patient would be classified as surgical patient in this subgroup.

249

250 A separate analysis for autoimmune thyroid disease to examine the association with
251 breast cancer showed no statistical significance (OR 0.94, 95% CI 0.68-1.29, $p=0.685$
252 for Hashimoto; OR 1.20, 95% CI 0.96-1.50, $p=0.109$ for Graves'). We also performed an
253 additional analysis with the exclusion of those who only had a 'one-time' diagnosis of
254 thyroid disorder during an inpatient admission to eliminate possible inpatient admission
255 bias. In the breast cancer group, there were 22 patients with only one-time
256 hypothyroidism diagnosis and 77 patients with only one-time hyperthyroidism diagnosis
257 out of 335 and 1580 patients respectively; while in the control group, 17 patients with
258 only one-time hypothyroidism diagnosis out of 291 and 82 patients with only one-time
259 hyperthyroidism diagnosis out of 1453 patients. After excluding those with only one-time
260 diagnosis of hyperthyroidism or hypothyroidism, the results showed similar associations
261 as above. Hyperthyroidism in all age groups showed an overall increased risk by 13% in
262 breast cancer development (adjusted OR 1.13, 95% CI 1.05-1.21, $p=0.002$), while
263 hypothyroidism in all age groups had an 18% increased risk (adjusted OR 1.18, 95% CI
264 1.01-1.39, $p=0.043$).

265

266

267

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

268

269

270

271

DISCUSSION

This is the first study in an Asian population assessing the association between hyperthyroidism, hypothyroidism and breast cancer. Among a total of 103,466 women in our study, we found increased risks of developing breast cancer in patients with medical history of either hyperthyroidism or hypothyroidism despite treatment. The association is significant in patients under age 55 years old with hyperthyroidism.

Since Beaston first described using thyroid extract to treat metastatic breast cancer in the Lancet in 1896, many studies have investigated the relationship between thyroid hormone and cancers.^{21 22} Specific alterations of thyroid hormone receptors (TR) have been found in different types of carcinomas, including breast cancer, and many studies observed associations between the expression of TRs and the regulation of oncogenes.²²⁻²⁴ Several physiological similarities have been discovered between the thyroid gland and mammary gland. For one, both thyroid follicular cells and breast lactating cells store iodine through natrium-iodine symporter (NIS)-mediated iodine uptake.²⁵⁻²⁸ The oxidization of iodine in the alveolar mammary cells utilizes lactohydroperoxidase, which is mechanistically similar to peroxidase in thyroid glands.²⁹

289

290 Several *in vitro* studies have shown that high levels of thyroid hormones may possess

291 estrogen-like effects and may promote breast cancer proliferation and angiogenesis.^{5 13}

292^{22 24 30} It has also been shown that the activation of TR in mammary glands may induce

293 the differentiation and lobular growth of breast tissues, an effect similar to that seen with

294 estrogen.^{22 23} Active triiodothyronine (T3) has been found to promote breast cancer cell

295 proliferation and to increase the effect of 17beta-estradiol (E2)-mediated cell

296 proliferation in some breast cancer cell lines.¹³ In population-based studies, T3 levels

297 have also been found to have a positive correlation with breast cancer tumor size and

298 the risk of lymph node metastasis.³¹

299

300 Hypothyroidism may trigger hypersensitization of mammary glandular epithelium to

301 estrogen and prolactin, possibly related to low circulating thyroid hormone, and further

302 lead to mammary dysplasia and neoplasia of the breast.^{17 18 32} Previous studies showed

303 a positive correlation between elevated serum prolactin level and an increased risk of

304 breast cancer,^{33 34} while other study also found that mild hyperprolactinemia did not

305 carry significant health risks and thus treatment was not required in post-menopausal

306 women.³⁵ The existence of a genetic predisposition for hypothyroidism and breast

307 cancer has been hypothesized as well.^{6 10}

308

309 We did not find a statistically significant association between autoimmune thyroid

310 disease (AITD) and breast cancer risk in this study. However, several studies have

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

311 shown that there may be a possible association between AITD and breast cancer, but
312 controversial in AITD and breast cancer survival. A study by Jiskra *et al.* found a higher
313 prevalence of euthyroid AITD in women with breast cancer and no prognostic impact
314 from AITD on breast cancer survival.³⁶

315
316 In our study, the significantly increased risk of breast cancer among patients with the
317 diagnosis of hyperthyroidism under 55 years of age is possibly related to higher levels
318 of thyroid hormone in addition to the physiological level of estrogen. The increased risk
319 drops from 15-16% to 5% with no statistical significance in hyperthyroidism patients >55
320 years of age. This is likely related to the menopausal status of these patients, an
321 indicator of low estrogen levels. In the further subgroup analysis, we found that
322 hyperthyroidism treatment with medications and/or surgery and thyroid replacement
323 treatment for hypothyroidism did not alter the risk of having breast cancer in the future.
324 While there is a 19% increased risk of breast cancer in hypothyroidism patients, the
325 statistical significance disappears when we stratify these patients into the 3 age groups.
326 Since there were only 335 patients with a diagnosis of hypothyroidism who developed
327 breast cancer, dividing this group into 3 age cohorts led to a decrease in power. Based
328 on our overall results, however, we can hypothesize that there is no protective effect of
329 hypothyroidism in the development of breast cancer. Interestingly, the use of estrogen-
330 containing products (which we controlled for) was not a contributing factor to an
331 increased risk of breast cancer in this study.

332

In 2017, it is estimated that 40,610 women may die of breast cancer in the U.S.¹ Current breast cancer screening guidelines published by the U.S. Preventive Services Task Force (USPSTF) recommend biennial screening mammography for women at average risk aged 50 to 74 years.³⁷ The American Cancer Society (ACS) recommends annual screening mammography for women at average risk aged 45 to 55 years then biennial screening after 55 years of age.³⁸ Our nationwide population-based study showed a significantly increased breast cancer risk in Asian women with medical history of hyperthyroidism under the age of 55 years and an increased risk or at least no protective effect of hypothyroidism. More studies are needed to examine this association in different age groups.

Limitations

The findings from our study were derived from a large population-based dataset; this minimized selection bias. The case-control study design using an administrative claims database reduced the recall bias; however, the findings might be less accurate due to the lack of supporting laboratory data; this includes thyroid antibody, TSH and thyroid hormones levels as well as breast cancer stages and receptor status. In order to minimize bias, we only studied those with a diagnosis of hyper- or hypothyroidism who were documented as having these diagnoses in at least three outpatient visits or one inpatient admission. All breast cancer patients in this study had the diagnosis of breast cancer and possessed the certificate of catastrophic illness. To avoid false claims, the National Health Insurance Bureau (NHIB) randomly samples a fixed percentage of claims from each hospital every year to confirm diagnosis validity, and medical records

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

were independently reviewed by professional experts. Since this study is based on administrative claims, the results may be underestimated or overestimated, as only patients who seek medical attention were evaluated and treated. Since thyroid disorders are often chronic diseases rather than acute onset, we thought that it might not be as useful to adjust the time lapse from the diagnosis of thyroid disorder to breast cancer.

Conclusion

Our nationwide Asian population-based study suggests that Asian women under the age of 55 years with medical history of hyperthyroidism have a significantly increased risk of developing breast cancer regardless of treatment. Women with a history of hypothyroidism may also have an increased risk. Further studies are needed to assess the association between age, hypothyroidism, and breast cancer risk.

374

375

376

377

378 **Author contributions:**

379 **Concept of study:** C-H Weng and T-H Lin

380 **Study design:** C-H Weng, X Luo, C-H Lin and T-H Lin

381 **Statistical analysis:** Y-H Chen and C-H Lin

382 **Interpretation of results:** C-H Weng, Y-H Chen, X Luo, and C-H Lin

383 **Manuscript writing:** C-H Weng

384 The other authors provided inputs, expertise, and critical review of the manuscript.

385 **C-H Weng and T-H Lin contributed as co-senior authors to this article.**

386

387

388

389

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

390

391

392

393

394 **Acknowledgements**

395 Special thanks to Professor & Chair Martha A. Zeiger, MD, FACS, FACE, Department of

396 Surgery, University of Virginia, Professor Christopher B. Umbricht, MD, PhD,

397 Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore,

398 MD, and Dr. Erin R. Okawa, MD, Boston Childrens Hospital Division of Endocrinology,

399 Boston, MA, for reviewing the manuscript and their comments.

400 The preliminary results from this study have been presented in part at the 86th Annual

401 Meeting of the American Thyroid Association in Denver, CO by Chien-Hsiang Weng,

402 MD, MPH, September 21-25, 2016. Authors thank all the comments and advices from

403 the conference.

404 This study has been approved by the Institutional Review Board of Taichung Veterans

405 General Hospital, Taichung, Taiwan (IRB # CE13151B-3). The study is based in part on

406 data from the National Health Insurance Research Database provided by the Bureau of

407 National Health Insurance, Department of Health and managed by National Health

408 Research Institutes. The interpretation and conclusions contained herein do not

represent those of National Health Insurance Administration, Department of Health or National Health Research Institutes.

Declaration of interest: The authors declare no potential conflicts of interest.

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Data sharing: Extra data is available by emailing the Corresponding author (jth.lin@gmail.com).

References

1. U.S. Breast Cancer Statistics. http://www.breastcancer.org/symptoms/understand_bc/statistics 2017
2. American Thyroid Association. <http://www.thyroid.org/media-main/about-hypothyroidism/> 2017
3. SEER Stat Fact Sheets: Female Breast Cancer, 2017.
4. Khan SR, Chaker L, Ruiter R, et al. Thyroid Function and Cancer Risk: The Rotterdam Study. *J Clin Endocrinol Metab* 2016;101(12):5030-36. doi: 10.1210/jc.2016-2104
5. Sogaard M, Farkas DK, Ehrenstein V, et al. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. *Eur J Endocrinol* 2016;174(4):409-14. doi: 10.1530/EJE-15-0989
6. Kuijpers JL, Nyklicek I, Louwman MW, et al. Hypothyroidism might be related to breast cancer in post-menopausal women. *Thyroid* 2005;15(11):1253-9. doi: 10.1089/thy.2005.15.1253

1
2
3 429 7. Angelousi AG, Anagnostou VK, Stamatakis MK, et al. Mechanisms in endocrinology: primary HT and
4
5 430 risk for breast cancer: a systematic review and meta-analysis. *Eur J Endocrinol* 2012;166(3):373-
6
7 431 81. doi: 10.1530/EJE-11-0838
8
9
10 432 8. Tseng FY, Lin WY, Li CI, et al. Subclinical hypothyroidism is associated with increased risk for cancer
11
12 433 mortality in adult Taiwanese-a 10 years population-based cohort. *PLoS One*
13
14 434 2015;10(4):e0122955. doi: 10.1371/journal.pone.0122955
15
16 435 9. Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. *Cancer Res*
17
18 436 1990;50(8):2283-9.
19
20
21 437 10. Smyth PP. The thyroid and breast cancer: a significant association? *Ann Med* 1997;29(3):189-91.
22
23 438 11. Morabia A, Szklo M, Stewart W, et al. Thyroid hormones and duration of ovulatory activity in the
24
25 439 etiology of breast cancer. *Cancer Epidemiol Biomarkers Prev* 1992;1(5):389-93.
26
27
28 440 12. Tosovic A, Bondeson AG, Bondeson L, et al. Prospectively measured triiodothyronine levels are
29
30 441 positively associated with breast cancer risk in postmenopausal women. *Breast Cancer Res*
31
32 442 2010;12(3):R33. doi: 10.1186/bcr2587
33
34 443 13. Hall LC, Salazar EP, Kane SR, et al. Effects of thyroid hormones on human breast cancer cell
35
36 444 proliferation. *J Steroid Biochem Mol Biol* 2008;109(1-2):57-66. doi: 10.1016/j.jsbmb.2007.12.008
37
38
39 445 14. Moeller LC, Fuhrer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical
40
41 446 perspective. *Endocr Relat Cancer* 2013;20(2):R19-29. doi: 10.1530/ERC-12-0219
42
43 447 15. Smith GL, Smith BD, Giordano SH, et al. Risk of hypothyroidism in older breast cancer patients
44
45 448 treated with radiation. *Cancer* 2008;112(6):1371-9. doi: 10.1002/cncr.23307 [published Online
46
47 449 First: 2008/01/24]
48
49
50 450 16. Khan NF, Mant D, Carpenter L, et al. Long-term health outcomes in a British cohort of breast,
51
52 451 colorectal and prostate cancer survivors: a database study. *Br J Cancer* 2011;105 Suppl 1:S29-37.
53
54 452 doi: 10.1038/bjc.2011.420 [published Online First: 2011/11/09]
55
56
57
58
59
60

17. Mittra I. Mammatropic effect of prolactin enhanced by thyroidectomy. *Nature* 1974;248:525. doi: 10.1038/248525a0
18. Vorherr H. Thyroid disease in relation to breast cancer. *Klin Wochenschr* 1978;56(23):1139-45. [published Online First: 1978/12/01]
19. Fang Y, Yao L, Sun J, et al. Does thyroid dysfunction increase the risk of breast cancer? A systematic review and meta-analysis. *J Endocrinol Invest* 2017 doi: 10.1007/s40618-017-0679-x
20. Kuo JH, Chabot JA, Lee JA. Breast cancer in thyroid cancer survivors: An analysis of the Surveillance, Epidemiology, and End Results-9 database. *Surgery* 2016;159(1):23-9. doi: 10.1016/j.surg.2015.10.009 [published Online First: 2015/11/03]
21. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. *The Lancet* 1896;148(3803):162-65. doi: 10.1016/S0140-6736(01)72384-7
22. Conde I, Paniagua R, Zamora J, et al. Influence of thyroid hormone receptors on breast cancer cell proliferation. *Ann Oncol* 2006;17(1):60-4. doi: 10.1093/annonc/mdj040
23. Gonzalez-Sancho JM, Garcia V, Bonilla F, et al. Thyroid hormone receptors/THR genes in human cancer. *Cancer Lett* 2003;192(2):121-32.
24. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. *Oncogene* 2002;21(5):761-8. doi: 10.1038/sj.onc.1205136
25. Smyth PP, Shering SG, Kilbane MT, et al. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. *J Clin Endocrinol Metab* 1998;83(8):2711-6. doi: 10.1210/jcem.83.8.5049
26. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. *Nature* 1996;379(6564):458-60. doi: 10.1038/379458a0

1
2
3 477 27. Chung JK. Sodium iodide symporter: its role in nuclear medicine. *J Nucl Med* 2002;43(9):1188-200.
4
5 478 28. Turken O, Narln Y, Demlrbas S, et al. Breast cancer in association with thyroid disorders. *Breast*
6
7 479 *Cancer Res* 2003;5(5):R110-3. doi: 10.1186/bcr609
8
9
10 480 29. Fierabracci P, Pinchera A, Campani D, et al. Association between breast cancer and autoimmune
11
12 481 thyroid disorders: no increase of lymphocytic infiltrates in breast malignant tissues. *J Endocrinol*
13
14 482 *Invest* 2006;29(3):248-51. doi: 10.1007/BF03345548
15
16 483 30. Nogueira CR, Brentani MM. Triiodothyronine mimics the effects of estrogen in breast cancer cell
17
18 484 lines. *J Steroid Biochem Mol Biol* 1996;59(3-4):271-9.
19
20
21 485 31. Tosovic A, Bondeson AG, Bondeson L, et al. T3 levels in relation to prognostic factors in breast cancer:
22
23 486 a population-based prospective cohort study. *BMC Cancer* 2014;14:536. doi: 10.1186/1471-
24
25 487 2407-14-536
26
27
28 488 32. Kwa HG, van der Gugten AA, Sala M, et al. Effect of pituitary tumours and grafts on plasma prolactin
29
30 489 levels. *Eur J Cancer* 1972;8(1):39-54. [published Online First: 1972/02/01]
31
32 490 33. Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women. *Breast*
33
34 491 *Dis* 2005;24:3-15. [published Online First: 2006/08/19]
35
36
37 492 34. Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. *Cancer Lett* 2006;243(2):160-9. doi:
38
39 493 10.1016/j.canlet.2006.01.032 [published Online First: 2006/03/15]
40
41 494 35. Schlechte JA. Clinical practice. Prolactinoma. *N Engl J Med* 2003;349(21):2035-41. doi:
42
43 495 10.1056/NEJMcp025334 [published Online First: 2003/11/25]
44
45
46 496 36. Jiskra J, Barkmanova J, Limanova Z, et al. Thyroid autoimmunity occurs more frequently in women
47
48 497 with breast cancer compared to women with colorectal cancer and controls but it has no impact
49
50 498 on relapse-free and overall survival. *Oncol Rep* 2007;18(6):1603-11. [published Online First:
51
52 499 2007/11/06]
53
54
55
56
57
58
59
60

- 1
2
3 500 37. Siu AL, Force USPST. Screening for Breast Cancer: U.S. Preventive Services Task Force
4
5 501 Recommendation Statement. *Ann Intern Med* 2016;164(4):279-96. doi: 10.7326/M15-2886
6
7 502 38. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015
8
9 503 Guideline Update From the American Cancer Society. *JAMA* 2015;314(15):1599-614. doi:
10 504 10.1001/jama.2015.12783
11
12
13
14
15
16 505
17
18
19 506
20
21
22 507 **Figure legend:**
23
24
25 508 Figure 1. Flow Diagram of Participants Selection and Study Design
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 1. Flow Diagram of Participants Selection and Study Design

12x4mm (600 x 600 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3	Nationwide population-based study
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3	Findings and Interpretation
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5	Paragraph 1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	5	Paragraph 3
Methods				
Study design	4	Present key elements of study design early in the paper	5	Paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	Paragraph 1
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	8	Breast cancer Case-control match Hyperthyroidism and hypothyroidism
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	8	Case-control match
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7	
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7	NHIRD & RCPD & LHID Hyper-/hypothyroidism, breast cancer
Bias	9	Describe any efforts to address potential sources of bias	2	Limitations of study

Study size	10	Explain how the study size was arrived at	84	51,733 patients in each group
------------	----	---	----	-------------------------------

For peer review only

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10	Statistical analysis paragraph
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10	
		(b) Describe any methods used to examine subgroups and interactions	10	
		(c) Explain how missing data were addressed	N/A	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	8-9	Case-control match paragraph
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed		
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy		
		(e) Describe any sensitivity analyses	N/A	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7-9 & Fig 1	
		(b) Give reasons for non-participation at each stage	7-9 & Fig 1	
		(c) Consider use of a flow diagram	Fig	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11	Paragraph 1 and Table 1
		(b) Indicate number of participants with missing data for each variable of interest	N/A	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	N/A	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	12-16	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	N/A	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12-16	
		(b) Report category boundaries when continuous variables were categorized	12-16	Paragraphs and Table 2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14-16 and Table 1	
Discussion				
Key results	18	Summarise key results with reference to study objectives	17	Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-22	Paragraph 2-6
Generalisability	21	Discuss the generalisability (external validity) of the study results	19-22	
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23	Acknowledgement

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.